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ABSTRACT 
 
CRYSTAL DODSON: Diffusion of Innovation: Knowledge and Attitudes of Oncology 
Nurses Regarding Pharmacogenomic Testing  
(Under the direction of Marcia Van Riper, PhD, RN, FAAN) 
 
 There are currently over 20 different pharmacogenomic tests being used in the 
oncology field.  However, only a few studies have been conducted regarding knowledge 
and attitudes towards pharmacogenomic testing among clinicians, in particular nursing.  
This descriptive study (guided by Rogers‟ Diffusion of Innovation Theory) utilizing 
descriptive statistics and variable selection methods was conducted with 368 oncology 
nurses in the state of North Carolina to identify and test key elements of Rogers‟ 
Diffusion of Innovation theory that play a role in the adoption of pharmacogenomic 
testing into the oncology practice by assessing oncology nurses knowledge, attitudes, and 
support for use of pharmacogenomic testing. 
 Oncology nurses who participated in this study had a low perception of their 
knowledge of both genomics and pharmacogenomic testing based on their perceived 
knowledge.  Additionally, attitudes towards pharmacogenomic testing were overall 
positive.  Attitudes toward pharmacogenomic testing specifically related to oncology had 
a more favorable response than attitudes towards pharmacogenomic testing in general.  
Furthermore, the study revealed that oncology nurses in this study utilize 
pharmacogenomic testing information routinely in their nursing care.  
  
  
 
iii 
Variable selection methods revealed that total genomic knowledge was more 
accurately predicted by prior experience and personality variables.  Secondly, basic 
genomic knowledge was more accurately predicted by prior experience, ruralality, 
perceived need of pharmacogenomic testing, and personality variables. Furthermore, 
pharmacogenomic knowledge was more accurately predicted by personality variables.  
Moreover, attitude towards pharmacogenomic testing was more accurately predicted by 
communication behavior, prior experience, perceived need and characteristics of the 
innovation. Finally, support for use was accurately predicted by perceived genomic 
knowledge. 
 Based on these findings, several factors play a key role in the diffusion of 
pharmacogenomic testing within the oncology nursing field.  Therefore, assessment of 
these variables may benefit the widespread adoption of pharmacogenomic testing.  
Further research should be conducted with these variables in order to assess the adoption 
of this innovation. 
 
 
 
 
 
 
 
 
 
 
  
 
iii 
DEDICATION 
To my wonderful and loving husband, Chad Dodson 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
iv 
ACKNOWLEDGEMENTS 
 I would like to thank Dr. Marcia Van Riper for her wonderful support throughout 
this process.  I am truly grateful for all the time and assistance she has provided me 
during my entire doctoral pursuit. I would also like to thank my committee, Dr. George 
Knafl, Dr. Howard McLeod, Dr. Theresa Swift-Scanlan, and Dr. Suzanne Thoyre, with 
my deepest appreciation for serving on my committee.   I would also like to thank my 
wonderful family for their support over the years while pursuing my educational 
endeavors.
  
 
v 
TABLE OF CONTENTS 
 
LIST OF TABLES ................................................................................................................... ix 
LIST OF FIGURES .................................................................................................................. x 
ABBREVIATIONS .................................................................................................................. xi 
Chapter 
          I.    INTRODUCTION .................................................................................................... 1 
                    Statement of the Problem ...................................................................................... 3 
                    Theoretical Framework ......................................................................................... 6 
                    Purpose of the Study ............................................................................................. 8 
                    Significance of the Study ...................................................................................... 8 
                    Summary ............................................................................................................. 10 
II.   LITERATURE REVIEW ........................................................................................11 
                    Conceptual Framework: Diffusion of Innovation ................................................11 
                    Concepts .............................................................................................................. 15 
                              Knowledge of Pharmacogenomic Testing ................................................ 15 
  Attitudes Concerning Pharmacogenomic Testing ..................................... 20 
  Support for Use of Pharmacogenomic Testing ......................................... 24 
  Diffusion of Innovation ............................................................................ 25 
  Prior Experience ....................................................................................... 26 
 
  
 
v 
  Perceived Need of Innovation .................................................................. 26 
                              Innovativeness........................................................................................... 26 
                              Norms of society (Work environment) ..................................................... 26 
                              Ruralality................................................................................................... 27 
                              Personality Variables ................................................................................. 27 
                              Communication Behavior ......................................................................... 28 
                              Relative Advantage ................................................................................... 28 
                              Compatibility ............................................................................................ 28 
                              Complexity ................................................................................................ 28 
                              Trialability ................................................................................................. 29 
                              Observability ............................................................................................. 29 
                    Summary ............................................................................................................. 29       
          III.  METHODODOLOGY ........................................................................................... 31 
                    Research Design.................................................................................................. 31 
                    Setting and Sample ............................................................................................. 32 
  Population ................................................................................................. 32 
  Eligibility Criteria ..................................................................................... 32   
                    Data Sources and Collection ............................................................................... 33 
                    Aims .................................................................................................................... 33 
                    Measurement of Variables ................................................................................... 35 
                    Instruments .......................................................................................................... 40 
  Knowledge, Attitude, and Support for Use Questionnaire (KAQ-PGx) .. 40 
  Innovativeness Scale (IS) ......................................................................... 42 
  
 
vi 
         Nursing Practice Questionnaire-Pharmacogenomic Testing  
         (NPQ-PGx). .............................................................................................. 43 
                    Protection of Human Subjects ............................................................................ 44 
                    Statistical Analyses ............................................................................................. 45                   
                    Summary ............................................................................................................. 50                       
          IV.  RESULTS ............................................................................................................... 51 
                    Sample Demographics ........................................................................................ 51 
                    Pharmacogenomic Utilization ............................................................................. 54 
                    Statistical Analyses ............................................................................................. 54 
                    Aim #1 Analyses ................................................................................................. 54 
                             Summary .................................................................................................... 59 
                    Aim #2 Analyses ................................................................................................. 60 
                             Summary .................................................................................................... 70 
                    Aim #3 Analyses ................................................................................................. 72 
                             Summary .................................................................................................... 80 
                    Aim #4 Analyses ................................................................................................. 83 
                             Summary .................................................................................................... 84 
                    Interest in Continuing Education ........................................................................ 85 
                    Summary ............................................................................................................. 86        
                                     
          V.  DISCUSSION .......................................................................................................... 87 
                    Key Findings ....................................................................................................... 87 
                              Perceived and Acutal Knowledge (Awareness) ........................................ 87 
         Attitude (Persuasion) Toward pharmacogenomic testing ......................... 87 
        Support for use (Decision) ......................................................................... 88 
  
 
vii 
                             Innovativeness............................................................................................ 88                                        
                    Concepts Related to Theory ................................................................................ 89 
                             
                    Relationships Associated with Knowledge (Awareness) .................................... 89 
 Total Genomic Knowledge ........................................................................ 89 
 Basic Genomic Knowledge ....................................................................... 91 
        Pharmacogenomic Knowledge .................................................................. 91 
                    Relationships Associated with Attitude (Persuasion)  ........................................ 92                          
                              Overall Attitude ......................................................................................... 92 
                              General Attitude ........................................................................................ 93 
  Attitude Specifically Related to the Field of Oncology ............................ 94 
                    Relationships Associated with Support for Use (Decision) ................................ 95 
                              Support for use .......................................................................................... 95  
                    Dicussion............................................................................................................. 95 
                    Strengths and Limitations ................................................................................... 98 
                              Strengths ................................................................................................... 98 
         Limitations ................................................................................................ 98 
                                       Study Tools ...................................................................................... 98 
                 Study Sample .................................................................................... 99 
                                      Study Variables ................................................................................. 99 
                    Implications for Education ................................................................................ 100 
                    Implications for Practice ................................................................................... 101 
                    Implications for Future Research ...................................................................... 102 
                    Summary ........................................................................................................... 103 
  
 
viii 
APPENDICES ...................................................................................................................... 105 
                    Appendix A: Data Request Form ...................................................................... 105 
       Appendix B:  Knowledge, Attitude, and Support for Use Questionnaire  
                             (KAQ-PGx) .................................................................................. 106 
 
                    Appendix C: Innovativeness Scale (IS) .............................................................117 
                    Appendix D: Informed Consent .........................................................................118                  
REFERENCES ......................................................................................................................119 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
ix 
LIST OF TABLES 
Table 
 
1.   Measurement of Concepts……………………………………………………… 36 
 
2.   Demographic Variables ………………...……………………………………… 52  
 
3.   Pharmacogenomic Testing Utilization ……………………………………….... 55 
 
4.   Nursing Practice Questionnaire..………...………………………………………55 
 
5.   Perceived Knowledge………………...………………………………………….58 
 
6.   Actual Genomic Knowledge……………………..………………………….…. 59 
 
7.   Attitude Scales…………………………..…………………………………….…60 
 
8.   Attitude Scale Items………………………………..…………………………….61 
 
9.   Support for Use…………………………………...……………………………...62 
 
10. Innovativeness…………………………………………………………………....63 
 
11. ANOVA-Actual Overall Genomic Knowledge………………….………………65 
 
12. ANOVA- Basic Genomic Knowledge…………………………………………..67 
 
13. ANOVA-Pharmacogenomic Knowledge…………………………….………….68 
 
14. Regression for Knowledge…………...………………………………………….71 
 
15. ANOVA-Overall Attitude……………………………………………………….75 
 
16. ANOVA-General Attitude………………………………………………………76  
 
17. ANOVA-Attitude Related to Oncology…………………………………………78 
 
18. Regression for Attitude…………..……………………………….…………….80 
 
19. ANOVA-Support for Use…………………………………………………...….84 
 
20. Regression for Support for Use…. …………………………………………….85 
 
 
 
  
 
x 
LIST OF FIGURES 
Figure 
 
1.   Rogers‟ Diffusion of Innovation Framework …………...………………………...7 
 
2.   Modified Version of Rogers‟ Innovation of Diffusion as Adapted by Dodson ....14  
 
3.   Perceived Genomic Knowledge ………...…………………………………….....57 
 
4.   Perceived Pharmacogenomic Knowledge..……………………………………....57 
 
5.   Diffusion of Innovation according to Rogers (2003)………………....………….63 
 
6.   Continuing Education Interest………………………………..………………….85 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
xi 
ABBREVIATIONS 
AIC  Akaike Information Criterion 
ANOVA Analysis of Variance 
APRN  Advanced Practice Registered Nurse 
BIC   Bayesian Information Criterion 
DNA  Deoxyribonucleic Acid 
DNP  Doctorate of Nursing Practice 
 
FDA  Food and Drug Administration 
 
KAQ-PGx Knowledge, Attitude, and Support for Use Questionnaire- 
                        Pharmacogenomic Testing 
 
LPN  Licensed Practical Nurse 
 
NPQ-PGx Nursing Practice Questionnaire-Pharmacogenomic Testing 
 
PG                   Pharmacogenomic 
 
PRESS  Predicted Residual Sums of Squares  
 
RN  Registered Nurse 
 
RNA  Ribonucleic Acid 
 
 
 
 
 
 
 
 
    
 
 
Chapter I 
Introduction   
During the past few decades there has been a dramatic increase in genomic 
testing.  The term genomic testing covers a wide array of sophisticated techniques 
including direct examination of DNA, RNA, or protein (National Human Genome 
Research Institute, 2012).  According to the GeneTests website, a publically funded 
medical genomics information resource, genomic testing is currently available for over 
2,500 diseases in the clinical setting (University of Washington, 2012).  In addition, 
testing for another 240 diseases is being carried out in research settings. Consequently, 
genomic testing will soon become available for a growing number of diseases.    
Genomic testing can be utilized for a multitude of reasons including confirmation 
of a suspected diagnosis, detection of the presence of a carrier state in individuals who 
appear unaffected, screening or diagnostic testing for genomic conditions in embryos, 
fetuses, and newborns, and prediction of a patient‟s response to different types of therapy 
(National Human Genome Research Institute, 2012).  Pharmacogenomic testing is a 
particular type of genomic testing that is used to guide a patient's drug therapy based on 
the individual‟s genomic make-up (Foley & Quigley, 2010).  The utilization of 
pharmacogenomic testing allows for the assessment of drug toxicity and effectiveness 
prior to the initiation of a specific drug (Benhaim, Labonte, & Lenz, 2012; Kitzmiller, 
Groen, Phelps, & Sadee, 2011; McLeod, 2004).  Pharmacogenomic testing is similar to 
other genomic tests in that it can be performed on a sample of blood or a buccal swab
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(National Institute of General Medical Sciences, 2012).  In addition, the techniques used 
to test for pharmacogenomic polymorphisms and genomic mutations are fundamentally 
the same as technique used in other types of genomic testing.  However, which 
populations are targeted and how test results are interpreted and utilized can be quite 
different.  For example, pharmacogenomic testing is only appropriate for patients who are 
candidates for treatment with particular medications (U.S. Food and Drug 
Administration, 2011), while other types of genomic testing are often considered 
appropriate for the general population. 
Several healthcare fields are currently benefiting from the use of 
pharmacogenomic testing.  One in particular is oncology.  At this time, there are over 20 
different pharmacogenomic tests being used in oncology (U.S. Food and Drug 
Administration, 2012). Pharmacogenomic tests are divided into two categories within the 
oncology field, ones that test for chemotherapy toxicity and ones that test responsiveness 
to treatment such as in tumor profiling (Genomic Diagnostic Network, 2012).  
Commonly used oncology drugs with pharmacogenomic testing information included in 
their package inserts are: Trastuzumab, Tamoxifen, Cetuximab, Vemurafenib, and 
Imatinib (U.S. Food and Drug Administration, 2012). 
On an annual basis, an estimated 1 out of every 7 in-patient hospitalizations 
experience an adverse drug reaction (Davies et al., 2009).  In addition, it has been 
reported that an adverse drug reaction is the fourth to sixth leading cause of mortality in 
the United States (Vora, Trivedi, Shah, & Tripathi, 2011).  The pervasiveness of adverse 
drug reactions is often thought to be the consequence of a one-size-fits-all philosophy in 
prescribing medications (Marsh & McLeod, 2006; Swen et al., 2007).  Therefore, in 
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recent years many researchers and clinicians have begun recommending a shift to 
individualized drug therapy.  Individualized drug therapy is an approach in which a 
patient‟s genomic profile is used to guide the type and amount of medication the patient 
receives (Hamburg & Collins, 2010; Roederer, Van Riper, Roederer, McLeod, & Evans, 
2012).  There is growing evidence that adverse reactions can be decreased when a 
patient‟s dosage of medication is based on their genomic profile (Amur, Zineh, 
Abernethy, Huang, & Lesko, 2010; Anderson et al., 2007, Becquemont, 2009; 
Manolopoulos, 2007; Phillips et al., 2001). 
Statement of the Problem 
Pharmacogenomic testing is becoming a routine part of practice in some areas but 
in others areas this is not the case (Ferraldeschi & Newman, 2011; Mutsatsa & Currid, 
2012).  The integration of pharmacogenomic testing into clinical practice ultimately 
depends on acceptance of and requests for pharmacogenomic testing by clinicians and 
patients (Rogausch , Prause, Schallenberg, Brockmoller, & Himmel, 2006).  Clinicians 
who have limited awareness of pharmacogenomic testing or lack an adequate 
understanding of the potential benefits of pharmacogenomic testing are less likely to have 
favorable attitudes about pharmacogenomic testing (Ghaddar, Cascorbi, & Zgheib, 2011).  
Other factors that may influence attitudes about pharmacogenomic testing include access 
to genomic specialists, availability of educational resources about pharmacogenomic 
testing, and the existence of well-defined clinical guidelines (Haga, Tindall, & O‟Daniel, 
2012).   
Currently, a few studies have been conducted regarding knowledge of and 
attitudes towards pharmacogenomic testing among clinicians (Haga et al., 2012, 
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Rogausch et al., 2006).  However, the studies that do exist suggest that while some 
clinicians view their understanding of pharmacogenomics to be good, the majority do not. 
A nationwide survey of 10,303 physicians revealed that only 10.3% felt adequately 
informed about pharmacogenomics (Stanek et al., 2012).  In contrast, a case study 
revealed that the four study participants whom were interviewed felt that pharmacists had 
a good understanding of pharmacogenomic testing (El-Ibiary, Cheng, & Alldredge, 
2008).  Moreover, in a study that included over 2000 clinicians and students from a 
variety of disciplines including pharmacy, nursing, and medicine, most of the participants 
described their knowledge of pharmacogenomic testing  to be fair (44%) or poor (34%).  
In addition, on the 5 knowledge-based questions about pharmacogenomic testing about 
more than half of study answered the majority of questions correctly (Van Riper et al., 
2012).    
Findings from studies about attitudes towards pharmacogenomic testing suggest 
that many clinicians have ethical concerns.  Some of the most commonly reported ethical 
concerns about pharmacogenomic testing are concerns about discrimination, lack of 
privacy, and failure to obtain informed consent (Avard, Silverstein, Sillon, & Joly, 2009; 
Egalite, Ozdemir, & Godard, 2007; Haga et al., 2011; Hedgecoe, 2006; Roederer et al., 
2012; Rogausch et al., 2006; Tamaoki, Gushima, & Tsutani, 2007; Van Riper et al., 
2012).  However, positive attitudes towards pharmacogenomic testing were also reported.  
The advantages of pharmacogenomic testing acknowledged by clinicians were a 
reduction in adverse drug reactions and better clinical outcomes (Avard et al., 2009; 
Egalite et al., 2007; Fargher et al., 2007; Hoop, Lapid, Paulson, & Roberts, 2010; Mrazek 
et al., 2007; Roederer et al., 2012; Rogausch et al., 2006; Tamaoki et al., 2007; Van Riper 
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et al., 2012).  In addition, two studies revealed that clinicians are more apt to use these 
tests because of the improved predictive accuracy of the prescribed drugs (Haga et al., 
2011; Payne et al., 2011).  According to the literature, clinicians have varying attitudes 
towards pharmacogenomic testing which may be related to the uncertainty of new 
innovations that have promising outcomes.   
Many barriers have been linked to the successful adoption of pharmacogenomic 
testing into practice.  Some of these barriers include lack of clinicians‟ awareness or 
knowledge, lack of counselors available, cost-effectiveness of this type of testing, 
substandard ethical regulations on genomic information, and inadequate evidence based 
outcomes relating to this type of testing (Ghaddar et al., 2011; Haga et al., 2011; Schnoll 
& Shields, 2011; Squassina et al., 2010).  However, one study revealed that clinicians did 
not feel that inferior ethical regulations were a barrier to the implementation of 
pharmacogenomic testing (Ghaddar et al., 2011).  Additionally, a study with third year 
medical students revealed that they were not concerned with ethical barriers; however, 
the plan for disclosure to patients varied greatly among these respondents (Zgheib, Arawi, 
Mahfouz, & Sabra, 2011).  Based on the literature, these barriers may play a role in the 
successful adoption of pharmacogenomic testing. 
In summary, lack of knowledge about and variable attitudes towards 
pharmacogenomic testing seem to permeate the healthcare field.  However, few studies 
currently exist on this topic and most have not been conducted with nurses.  Additionally, 
there has only been one published study about attitudes toward pharmacogenomic testing 
among professionals within the oncology field (Hedgecoe, 2006).  Moreover, there have 
been no published studies concerning the knowledge of oncology clinicians related to 
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pharmacogenomic testing.  Information obtained from a systematic review of the 
empirical literature revealed that there is a significant gap pertaining to the attitudes and 
understanding of pharmacogenomic testing within the oncology nursing population.  Due 
to the relation between knowledge, attitudes, and adoption of pharmacogenomic testing, a 
study focusing on the assessment of knowledge and attitudes as it relates to support for 
use of pharmacogenomic testing within the oncology nursing population was conducted. 
Theoretical Framework 
 Everett Rogers‟ Diffusion of Innovation theory provided the framework for 
examining the process of adoption and diffusion of pharmacogenomic testing among 
oncology nurses (Rogers, 2003).  An innovation is defined as an idea, practice, or object 
that is perceived as new by an individual (Rogers, 2003).  Adoption of an innovation is a 
decision-making process in which the individual first passes from initial knowledge of 
the innovation to forming an attitude toward this innovation, to a decision to either accept 
or reject it, or wait to make a decision at a later date.  Factors that influence this decision 
are of utmost importance because this decision leads to the utilization of the innovation 
into practice.  The stages of adoption and diffusion of an innovation are shown in Figure 
1.  
The first step in the adoption of an innovation is the initial knowledge about the 
innovation (Rogers, 2003).  According to Rogers‟ (2003), there are several antecedents 
that affect how knowledge is received such as prior experience, perceived need of the 
innovation, general attitude towards change, personality variables such as age and 
educational level, demographic variables, communication behavior, and the work 
environment of the individual.   
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Figure 1:  Rogers‟ Diffusion of Innovation framework.  This figure displays the stages of  
this framework. 
 
The awareness of the innovation then motivates the individual to gain more information 
about the topic.  However, knowledge of the innovation does not automatically lead to 
adoption due to the fact that the individual must be persuaded to accept the innovation.  
The decision to adopt the innovation relies on the attitude of the individual concerning 
the innovation.  Certain characteristics such as relative advantage, complexity, 
compatibility, trialability, and observability influence the individual‟s attitude toward the 
innovation (Rogers, 2003).  Once a decision has been made to adopt it, the innovation is 
put into use and finally an evaluation of the innovation is completed. 
 This theory proposed a helpful way of assessing factors that may influence the 
diffusion of an innovation such as pharmacogenomic testing.  The theory provided 
several factors of the decision-making process to consider as critical inputs that have the 
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potential to influence the adoption process of the innovation.  These factors were utilized 
in the creation of specific variables to target within this study.    
Purpose of Study 
 The purpose of this study was to identify and test key elements of Rogers‟ 
Diffusion of Innovation theory that play a role in the adoption of pharmacogenomic 
testing into the oncology practice by assessing oncology nurses knowledge, attitudes, and 
support for use of pharmacogenomic testing.  
Significance of the Study 
 Scientific knowledge of genomics has exponentially increased in the first decade 
of the 21st century.  The growing applicability of genomic testing raises concerns 
surrounding the expanding knowledge deficit as well as multiple ethical concerns related 
to genomic testing. Genomic information has the potential to have a profound effect on 
our attitudes regarding the equal distribution of healthcare in our society (Cappelen, 
Norheim, & Tungodden, 2008).  Nurses need to understand genomic information and 
implications for practice in order to permit incorporation of genomics into nursing care, 
enhance an attitude of approval towards genomics, provide more holistic care, and 
advocate better for their patients (Prows, 2011; Williams, Skirton, & Masny, 2006).  The 
American Nursing Association (ANA) and the Institute of Medicine (IOM) have both 
identified the need for nurses who are prepared to take part in genomic health care 
services.  However, inconsistent training and education in genomics continues to 
permeate nursing and other health care fields (Challen et al., 2005; Cragun, Couch, 
Prows, Warren, & Christianson, 2005; Forbes & Hickey, 2009). 
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Furthermore, pharmacogenomic testing, a specific type of genomic testing, is 
becoming more prominent in clinical practice.  Currently there are 104 Food and Drug 
Administration (FDA)-approved drugs with pharmacogenomic information in their labels 
(U.S. Food and Drug Administration, 2012).  Out of these FDA-approved drugs, 28 of 
them are directly related to oncology.  Nurses are at the forefront of patient care, which 
makes them perfectly positioned to educate patients about new and innovative 
technologies associated with their health care.  Therefore, nurses could play a critical role 
in the incorporation of pharmacogenomic testing and genotype-guided therapy into 
routine practice, especially with oncology patients.  
There is growing evidence that a substantial contributor to cancer drug therapy is 
the patient‟s own genomic makeup (Prows, 2011).  As noted previously, a multitude of 
pharmacogenomic tests are used in a variety of oncology settings for many different 
forms of cancers.  Therefore, oncology nurses must become well-informed about 
pharmacogenomic testing in order to accurately administer cancer drugs and monitor the 
patient‟s response.  Nurses need to be aware that both genomic and non-genomic factors 
contribute to side effects and toxicity. Moreover, nurses need to integrate this information 
into the teaching they do with patients and families. Additionally, they need to encourage 
patients and their families to watch for and report side effects and early signs of toxicity.  
Also oncology nurses need to be aware that additional pharmacogenomic testing may be 
necessary based on the specificity of this type of genomic testing.  Pharmacogenomic 
testing only tests for specific gene variants.  Therefore as technology expands and testing 
becomes available for additional gene variants, patients may benefit from additional 
pharmacogenomic testing. 
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Nurses, especially oncology nurses, have an important role in making sure that 
patients and families are informed about the purpose and limitations of pharmacogenomic 
testing. However, to do this, nurses must be accepting of, and knowledgeable about this 
type of genomic testing and therapy.  Nurses who are knowledgeable about this type of 
testing and therapy will be able to become advocate and discuss the benefits and 
limitations of this therapy with patients and their families.  Consequently, studies like this 
which provide an assessment of oncology nurses‟ knowledge, attitude, and support for 
use of pharmacogenomic testing will provide a baseline for deficits in knowledge and 
ethical concerns regarding pharmacogenomic testing among this population. 
Summary 
 Pharmacogenomic testing is a relevant topic within the oncology setting and has a 
significant impact on the nursing care provided to these patients and their families.  
Rogers‟ Diffusion of Innovation theory was the conceptual framework that provided a 
basis for assessing variables that are related to the adoption of pharmacogenomic testing 
within the oncology field.  It is often the individual‟s attitude that determines the rate of 
diffusion once the new knowledge is available.  Therefore, this study and other research 
examining key elements that may affect the adoption of pharmacogenomic testing by 
oncology nurses will provide valuable insights that can be used in the development of 
interventions designed to facilitate the widespread adoption of pharmacogenomic testing 
in clinical practice. 
 
 
 
    
 
 
Chapter II 
Literature Review 
Conceptual Framework: Diffusion of Innovation   
 The adoption of a new idea is often times very difficult despite many obvious 
advantages that this new idea may provide (Rogers, 2003).   According to Rogers (2003), 
often many years pass before an innovation is widely adopted.  An innovation is defined 
as an idea, practice, or object that is perceived as new by an individual (Rogers, 2003).  
Despite the fact that the word „pharmacogenomics‟ was coined in 1959 by Friedrich 
Vogel of Heidelberg, Germany, widespread adoption of this new idea is still forthcoming 
(Motulsky & Qi, 2006).  Nurses are among several disciplines that are now being 
introduced to pharmacogenomic testing as a new innovation.   
 Adoption of an innovation is a time-consuming process due to the fact that 
diffusion of the innovation must take place through the appropriate channels within the 
social system (Rogers, 2003).  This process can be extensive at times, which makes this 
process difficult.  Diffusion is the passive spread by which an innovation is 
communicated through certain channels within the social system over time (Rogers, 
2003).  Whereas dissemination is the active process that increases the awareness and 
adoption.  According to Rogers (2003), mass media channels are more effective in 
generating knowledge about the innovation, whereas interpersonal channels are more 
effective in establishing and altering attitudes towards a new idea.
    
 
12 
Finally, implementation is the planned efforts to put the idea into clinical practice 
(Greenhalgh, Robert, Macfarlane, Bate, & Kyriakidou, 2004).  The elements of the 
diffusion of innovation process are shown in Figure 1.   This framework was utilized to 
describe the process by which the idea of pharmacogenomic testing is diffused through 
the field of nursing.  The characteristics of the innovation, as perceived by the 
individuals, determine the rate of adoption.   
Additionally, an individual‟s innovativeness also is a determinant of the time it 
takes to adopt an innovation.  Innovativeness is the degree to which an individual adopts 
new ideas as compared to other members of their social system.  There are five adopter 
categories based on their innovativeness: innovators, early adopters, early majority, late 
majority, and laggards.  Innovators are adventurous types that enjoy being on the cutting 
edge and like trying new ideas. The decision made by this type of individual within the 
implementation and confirmation stage is important to the subsequent decisions of other 
potential adopters.  Early adopters use the innovator‟s decision to make their own 
adoption decisions.  If the early adopters perceive that the innovation has been beneficial 
for the innovators, then they will adopt as well.  This group is well respected for its well-
informed decision-making.  Therefore this group is where most opinion leaders in a 
social system reside (Rogers, 2003).  The majority of the rest of the social system trust 
the decisions made by opinion leaders in order to be similar to others.  Once these 
opinion leaders adopt the innovation the rate of adoption rapidly increases and a large 
section of the social system follows, which are called the early majority and then 
subsequently the late majority joins.  Finally the last adopters are called the laggards and  
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they are considered very traditionalists or may be isolated from the rest of the social 
system, which decreases their rate of adoption of the innovation. 
Multiple studies have revealed that there are typically the same percentage of 
individuals distributed within each innovativeness category for all social systems.  This 
distribution should follow a bell-shaped curve and is utilized to assess whether a 
particular social system, such as oncology nursing, will have successful adoption of an 
innovation (Rogers, 2003) 
This research study focused on the first three stages of the Diffusion of Innovation 
theory, as shown in Figure 2.  It is important to understand what variables affect the 
development of knowledge and attitudes that may enhance the successful adoption of the 
innovation.  Information concerning ways to speed up the rate of diffusion, 
dissemination, and implementation of the innovation will lead to a more successful 
widespread uptake of this innovation.  
The first step focused on is initial awareness of the innovation.  According to 
Rogers (2003), there are several characteristics that affect how one receives new 
knowledge such as prior experience, perceived need of the innovation, general attitude 
towards change, ruralality, and the work environment of the individual.  This knowledge 
of the innovation then stimulates the individual to expand upon the information 
surrounding this topic. However, awareness of the innovation does not automatically lead 
to the decision to adopt this idea. The individual must then be persuaded to accept the 
innovation.   
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Figure 2: Modified Version of Rogers‟ Diffusion of Innovation as adapted by Dodson. This figure 
represents the stages of Rogers‟ Diffusion of Innovation used in this study. 
 
The persuasion step relies on the attitude of the individual concerning the 
innovation (Rogers, 2003).  Antecedents that affect the persuasion of an individual 
include relative advantage, complexity, compatibility, trialability, and observability.  
Relative advantage is the perception that the innovation is better than the current 
treatment.  Compatibility is the degree to which the innovation coexists with the 
individual‟s existing values, past experiences, and needs.   Complexity of the innovation 
is the degree of difficulty to comprehend. Trialability is the ability of the innovation to be 
incorporated into practice on a trial basis.  Finally, observability is the degree to which 
the innovation is visible to the individuals.  These characteristics influence the 
individual‟s attitude towards the innovation (Rogers, 2003).  Once a decision has been 
made to adopt it, the innovation is implemented and finally confirmation of the 
innovation is obtained.    
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Concepts 
 The review of the literature conducted for this study focused on two main 
concepts within the field of nursing: knowledge of pharmacogenomic testing and 
attitudes concerning pharmacogenomic testing.  Also a review of the literature 
surrounding support for use of pharmacogenomic testing and Rogers‟ Diffusion of 
Innovation model was conducted to identify key variables that may play a role in the 
process of diffusion of the innovation. 
Knowledge of pharmacogenomic testing.  Adequate competence in genomics as 
it relates to a nurse‟s specialized field supports the delivery of safe, quality care (Kirk, 
Calzone, Arimori, & Tonkin, 2011).  A panel of leaders from almost 50 organizations 
created a document that entails the critical nursing competencies for genomics entitled 
“Essential Nursing Competencies and Curricula Guidelines for Genomics and Genomics” 
(Prows, 2011).  This document describes the minimal genomic competencies for all 
registered nurses regardless of their practice setting or academic preparation.  One main 
competency that all nurses should possess is the ability to provide patients with accurate 
and appropriate information regarding genomic information, resources, and/or services 
that allows for better decision-making skills.  This competency allows the nurse to 
become a better patient advocate because nurses, who are knowledgeable about 
genomics, and more specifically pharmacogenomic testing, are better able to discuss the 
benefits and limitations of pharmacogenomic testing (Prows & Beery, 2008).  In addition, 
nurses must be able to adequately assess their patient‟s knowledge of pharmacogenomic 
testing; therefore nurses must have an adequate knowledge of pharmacogenomic testing 
so they can assess whether their patient has adequate knowledge or if clarification is 
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necessary (Prows & Saldana, 2009).  According to Prows and Saldana (p. 184, 2009), 
nurses need to know the following key points about pharmacogenomic (PG) testing:  
“(a) drug response is influenced by many different factors and bodily processes; 
(b) genomic test results provide a component of the necessary information when 
prescribers select and dose medications; (c) commercially available PG tests are 
not relevant for all medications; (d) genomic test results may be relevant to a 
patient's future health care because inherited genes, for the most part, do not 
change; (e) a patient's genomic test result may be relevant to biologic family 
members because they share inherited genes; and (f) depending on the type of 
analysis performed in the laboratory, a negative or normal test result may be a 
false negative if all possible variants associated with altered gene function were 
not analyzed.”  
While staff nurses are not responsible for ordering pharmacogenomic tests; 
however, as a patient advocate, it is within all nurses‟ scope of practice to be an active 
participant in their patient‟s care, which may include reminding prescribers that 
pharmacogenomic tests are available and should be considered.  Additionally, as 
pharmacogenomic testing becomes more widespread, all nurses will become accountable 
for applying genomic information when administering medications that are based on a 
genomic test.  Therefore, safe and optimal patient care will demand accurate and up-to-
date knowledge of genomic and pharmacogenomic testing by nurses in practice, research, 
and education (Read, 2002). Furthermore, Beery and Hern (2004) stated that most 
practicing advanced practice registered nurses (APRNs) are inadequately prepared to 
integrate genomic concepts and pharmacogenomics into their practice.  Due to this lack 
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of knowledge, in 2010, the Health Resources and Services Administration (HRSA) 
Expert Panel on Genomics and Nursing recommended that genomics is no longer an 
option but must be a part of nursing curriculum and continuing education programs 
(Beery & Hern, 2004). 
 Findings from a recent study of genetic/genomic competencies and nursing 
regulation in 10 countries (Kirk et al., 2011) revealed that only one of the countries 
included competencies in genomics and genomics in their regulatory standards for 
nursing and this was only at a “basic level”.  Kirk and colleagues argued that professional 
regulation of genomic/genomic competencies must be demonstrated in order for 
practicing nurses to gain the adequate knowledge base to provide safe and optimal care 
for their patients.  According to Prows and Beery (2008), the minimum genomic 
competencies for nurses will be to learn about basic genomic information, which will 
give a good introduction for the explanation and acceptance of pharmacogenomic testing 
among clinicians. 
Awareness of the knowledge and attitudes of genomic testing in general is 
pertinent to this study because it plays a large role in the knowledge and attitudes towards 
pharmacogenomic testing. A literature search of general knowledge towards genomic 
testing revealed a concerning knowledge deficit among the general public.  Henneman, 
Timmermans, and Van Der Wal (2006) conducted a study to assess the knowledge, 
experiences, and future expectations of genomic testing in the Dutch population.  Over 
half of the participants believed that they had a lower level of genomic knowledge 
compared to other Europeans and Americans.  Also 79% of the participants did not know 
that they were genomically related to their siblings.  In addition, knowledge of genomic 
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testing among healthcare professionals is deficient as well (Baars, Henneman, & Ten 
Kate, 2005; Dodson & Lewallen, 2011; Fargher et al., 2007; Hoop et al., 2010; Kadafour, 
Haugh, Posin, Kayser, & Shin, 2009). Dodson & Lewallen (2011) found that 76% of 
nursing students perceived their knowledge as minimal.  Also Kadafour et al. (2009) 
found that 66% of healthcare professionals felt they had a general lack of knowledge.  
These findings should in theory correlate with pharmacogenomic testing knowledge. 
After an extensive review of the literature, only nine research articles were 
located that reported findings from studies in which knowledge of pharmacogenomic 
testing among clinicians were assessed.  The majority of these studies revealed that 
clinicians felt that they had limited knowledge of pharmacogenomic testing (Dodson & 
Lewallen, 2011; Fargher et al., 2007; Hoop et al., 2010; Kadafour et al., 2009; Roederer 
et al., 2012; Tamaoki et al., 2007; Stanek et al., 2012; Van Riper et al., 2012).  However, 
findings from a case study in which 4 pharmacists were interviewed revealed that these 
participants believed that pharmacists are well informed about pharmacogenomic testing 
(El-Ibiary et al., 2008).  
Furthermore, in a study that included nurses, pharmacists, physicians, and 
healthcare students, the group with the lowest total mean score (2.5 out of 5) for the 
questions designed to assess knowledge of pharmacogenomic testing were practicing 
nurses (Van Riper et al., 2012).  Additionally, two studies had conflicting findings 
regarding the knowledge level of healthcare students. While findings from both studies 
(Dodson & Lewallen, 2011; Van Riper et al., 2012) indicated that healthcare students had 
higher perceived knowledge of genomics than practicing nurses, they disagreed about 
perceived knowledge of pharmacogenomic testing among healthcare students.  Findings 
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from the study conducted by Dodson and Lewallen revealed that 76% of nursing students 
in an undergraduate program reported minimal to no knowledge of pharmacogenomic 
testing.  In contrast, findings from the study by Van Riper et al. (2012) revealed that most 
healthcare students, including residents, pharmacy, and nursing students rated their 
knowledge of pharmacogenomic testing as excellent to very good.  In addition, healthcare 
students scored the highest on the knowledge based questions regarding 
pharmacogenomic testing with a mean score of 3.25 out of 5. 
 In a study by Hoop et al. (2010), clinicians who had pharmacogenomic testing 
available at their worksite had a significantly higher median knowledge score of 
pharmacogenomic testing (p = 0.03), as did those who used it (p= 0.009).  However, this 
study also revealed that 66% of all clinicians felt that they had a general lack of 
knowledge about pharmacogenomic testing.   This finding coincides with the results 
found throughout the majority of the literature review, which revealed that clinicians 
generally underestimate their knowledge.  Therefore, a perceived lack of knowledge 
concerning pharmacogenomic testing permeates this field, which reveals the need to test 
the actual knowledge of pharmacogenomic testing to gather accurate results regarding 
pharmacogenomic knowledge of clinicians. 
 Overall, there seems to be a pattern of a perception of a general lack of knowledge 
among all disciplines.  Only two studies utilized methods to obtain both perceived and 
actual knowledge of pharmacogenomic testing among clinicians (Kadafour et al., 2009; 
Van Riper et al., 2012).  Additionally, only four studies assessed the knowledge of nurses 
(Dodson & Lewallen, 2011; Fargher et al., 2007; Kadafour et al., 2009;Van Riper et al., 
2012).  These findings coincide with the conclusions found throughout other disciplines.  
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Furthermore, only one nursing study focused on the field of oncology and only included 
APRNs (Van Riper et al., 2012).  Van Riper et al. (2012) study revealed that it is 
imperative that nurses understand the difference between genomic tests that assess risk of 
disease versus tests that are used as a tool for the guidance of treatment related to tumor 
markers and medication decisions.  Therefore, this study looked at perceived and actual 
knowledge of different types of practicing nurses concerning pharmacogenomic testing 
specifically within the oncology field. 
Attitudes concerning pharmacogenomic testing.  Pharmacogenomic testing has 
the capability to affect major decisions for individuals and their families.  Therefore, all 
genomic testing must be utilized in a just and confidential manner.  According to Pestka 
(2003), nurses need to be especially aware of all factors involved with both testing and 
not testing, limitations of legal safeguards, family genograms that may reveal 
unsuspected information, cultural issues, and maintaining strict confidentiality.  Beery 
and Hern (2004) revealed that clinicians need to have the skills necessary to apply the 
appropriate ethical, social, cultural, and personal values based on genomic technology.  
The understanding of healthcare professional attitudes towards genomic technology will 
lead to a better comprehension of these necessary skills. 
Attitude is defined as “a favorable or unfavorable evaluative reaction toward 
something or someone exhibited in ones beliefs, feelings, or intended behavior” (Myers, 
2009, p. 36).  A person‟s attitude is often defined by social norms and helps organize 
their actions and provide a more predictable behavior.  Typically an attitude is formed 
from the experiences one encounters. Three basic components comprise an attitude: 
emotional, informational, and behavioral.  The emotional component involves one‟s 
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feelings or perception toward the concepts whether it is positive, negative, or neutral.  
The informational component consists of the beliefs and information one has concerning 
the particular concept.  Finally, the behavioral component consists of the tendency to 
conduct oneself in a particular way toward the concept.  
Clinicians must understand the psychological impact and implications for family 
members due to the ethical, legal and social issues associated with all genomic testing 
(Arnett, Claas, & Lynch, 2009).  Attitudes towards genomic testing in general will play a 
large part in the formation of one‟s attitude towards pharmacogenomic testing.  There has 
been a wide variety of research conducted on public attitudes concerning medical 
genomics.  Both positive and negative attitudes have been identified.  There are a few 
negative attitudes among the general public that have been consistent within the review 
of the literature.  Overall, the main concern with genomic testing was the possibility of 
discrimination from either employment or insurance (Bates, Lynch, Bevan, & Condit, 
2005; Haga et al., 2012; Henneman et al., 2006; Hietala et al., 1995; Jallinoja et al., 
1998).  Additionally a literature search revealed that clinicians also felt that genomic 
testing could potentially increase risk of discrimination by employment and insurance as 
well as fear of increased risk of breach of privacy (Freedman et al., 2003; Lawrence & 
Appelbaum, 2011). 
 Haga and Burke (2008) revealed that ethical issues related to pharmacogenomic 
testing were very similar to those associated with genomic testing such as the utilization 
of informed consent, timing of pharmacogenomic testing, and storage and retrieval of 
such testing, which seem to coincide with the general attitudes toward genomic testing in 
general.  Additionally, eight articles revealed that attitudes of clinicians concerning 
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pharmacogenomic testing concurred with the previous findings related to genomic testing 
in general due to the fact that clinicians felt that pharmacogenomic testing would lead to 
discrimination based on one‟s genomic tests (Egalite et al., 2007; Hedgecoe, 2006; Hoop 
et al., 2010; Rogausch et al., 2006;Van Riper et al., 2012; Zgheib, Arawi, Mahfouz, & 
Sabra, 2011).  Employment discrimination, insurance discrimination and racism were the 
terms frequently utilized in the qualitative studies.  Furthermore, Avard et al. (2009) and 
Egalite et al. (2007) had a distinctive theme of fear of racial profiling and stigmatization 
based on pharmacogenomic testing, though it tends to relate to the overall fear of 
discrimination. 
 Another common attitude towards pharmacogenomic testing among clinicians 
was the concern of lack of privacy (Avard et al., 2009; Hedgecoe, 2006; Hoop et al., 
2010; Tamaoki et al., 2007;Van Riper et al., 2012).  One study, which was conducted in 
2004 with clinicians, researchers, and leaders of drug companies and regulatory agencies, 
revealed that 40% of the sample feared that pharmacogenomic testing would lead to 
leakage of genomic information (Tamaoki et al., 2007).   
 Additionally, four of the articles revealed that clinicians believed that an informed 
consent was necessary for this type of procedure, despite the fact that a routine laboratory 
test does not require an informed consent (Avard et al., 2009; Hedgecoe, 2006; Hoop et 
al., 2010; Rogausch et al., 2006).  Over 85% of physicians felt that informed consent was 
necessary for this type of testing (Rogausch et al., 2006).  Another ethical concern of 
equal access to pharmacogenomic testing was revealed in two studies (Avard et al., 2009; 
Fargher et al., 2007). 
  Another common theme prevalent in Hedgecoe‟s (2006) study that 
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coincides with the concern for equal access is the increased expense of this type of 
testing.  
 A common perceived advantage of pharmacogenomic testing was a reduction in 
adverse drug reactions (Avard et al., 2009; El-Ibiary et al., 2008; Rogausch et al., 2006; 
Tamaoki et al., 2007; Van Riper et al., 2012).  Rogausch et al. (2006) revealed 
approximately 52% of physicians felt that pharmacogenomic testing had clinical utility 
and 54% felt that this would aid in the correct dosage of drugs, which would ultimately 
lead to a reduction in adverse drug reactions.  Avard et al. (2009) and El-Ibiary et al. 
(2008) agreed with the findings by Rogausch et al. (2006) in that researchers felt that 
there were several advantages of pharmacogenomic testing, including better reliability of 
tests in order to reduce adverse drug reactions.  However Kadafour et al. (2009) revealed 
a discrepancy among anticoagulation providers' perceptions regarding pharmacogenomic 
testing in that they were undecided about whether this testing will be more accurate or 
even decrease adverse drug reactions.    
 Furthermore, four studies revealed that pharmacogenomic testing would lead to 
overall better outcomes for patients (Egalite et al., 2007; Fargher et al., 2007; Roderer et 
al., 2012;Van Riper et al., 2012).  Fargher et al. (2007) and Payne et al. (2011) revealed 
that clinicians felt that pharmacogenomic testing would increase confidence in 
personalized medication dosage and prescription.  Additionally, Van Riper et al. (2012) 
agreed that pharmacogenomic testing will be overall beneficial to the patient because 
clinicians felt that pharmacogenomic testing would decrease the time it took to find the 
optimal dose for Warfarin (Van Riper et al., 2012).  
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 Overall, there are many ethical concerns related to pharmacogenomic testing.  
However, there are some positive aspects of pharmacogenomic testing according to these 
clinicians.  The majority of the ethical concerns were related to lack of privacy, need for 
informed consent, cost, and fear of discrimination (Avard et al., 2009; Egalite et al., 
2007; Hedgecoe, 2006; Rogausch et al., 2006; Tamaoki et al., 2007;Van Riper et al., 
2012).  The positive aspects of pharmacogenomic testing acknowledged by clinicians 
were a reduction in adverse drug reactions and better clinical outcomes (Avard et al., 
2009; Egalite et al., 2007; Fargher et al., 2007; Hoop et al., 2010; Mrazek et al., 2007; 
Rogausch et al., 2006; Tamaoki et al., 2007; Van Riper et al., 2012).  Lee, Ma, and Kuo 
(2010) also revealed that patient and clinicians must overcome ethical barriers such as 
fear of loss of privacy, genomic profiling, and stigmatization.  In addition, social issues 
such as the creation of health disparity should be focused upon due to many concerns 
related to this issue.  Finally, economic issues such as the cost effectiveness of certain 
tests should be addressed for all clinicians (Lee et al., 2010).  Many studies have been 
conducted on the attitude to pharmacogenomic testing in general, however, no studies 
have assessed the attitude of pharmacogenomic testing specifically related to oncology.  
Therefore, the current study assessed not only attitudes towards pharmacogenomic testing 
in general, but also attitudes specifically related to pharmacogenomic testing in the 
oncology field. 
Support for use of pharmacogenomic testing.  Integration of pharmacogenomic 
testing into routine practice ultimately depends upon clinicians' approval of, and query 
for, pharmacogenomic testing (Rogausch et al., 2006). For this study, support for use of 
pharmacogenomic testing was used to delineate the concept of adoption within Rogers‟ 
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Innovation of Diffusion theory.  This concept is defined as degree to which the 
respondent uses pharmacogenomic testing information in their practice.  In addition, 
support for use of pharmacogenomic testing was measured by the availability of 
pharmacogenomic testing within the healthcare field. 
One of most significant reasons for the utilization of pharmacogenomic testing is 
the reduction in adverse drug reactions.  Adverse drug reactions are the leading cause of 
hospitalization and are considered the fourth leading cause of in-patient death 
(Kongkaew, Noyce, & Ashcroft, 2008).  An estimated 1 out of every 7 in-patient 
hospitalizations are exposed to an adverse drug reaction every year (Davies et al., 2009).  
In addition, Lazarou, Pomeranz, and Corey (1998) conducted a meta-analysis of 
prospective studies related to serious and fatal adverse drug reactions and revealed that 
on average two million hospitalized patients suffer from an adverse drug reaction even 
when the medications are prescribed correctly.  These reactions can be dramatically 
decreased when dosage of medication is based on one‟s genomic profile (Amur et al., 
2010; Vora et al., 2011).
  
Therefore, nurses must recognize the opportunities available 
due to pharmacogenomic testing to develop successful strategies to best utilize genomic 
information into their practice because individualized care is optimal (Beery & Hern, 
2004).
 
Diffusion of innovation.  According to Rogers (2003), several variables 
potentially influence the adoption of an innovation.  Certain variables such as prior 
experience, perceived need of the adopters, innovativeness, norms of society, 
demographic variables, personality variables such as age and education, and 
communication behavior are antecedents to the knowledge stage within this decision-
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making process to adopt or reject an innovation.  In addition, perceived characteristics of 
the innovation which include relative advantage, compatibility, complexity, trialability, 
and observability also play a significant role in the decision-making process.  
Prior experience.  Earlier information revealed that before any innovation can be 
adopted, an individual must be made aware of the innovation (Zaltman, Duncan, & 
Holbek, 1973).  Previous innovation experience of the adopter can affect resistance to 
adopt the innovation.  Ram (1987) revealed that past experience can bias one‟s decision-
making process and is often called a „mind set.‟  This mind-set plays an important role in 
shaping the adopter‟s perception and attitude formation.  Therefore a positive previous 
innovative experience will increase the adoption of the innovation.   
Perceived need of innovation. According to Ram (1987), unless an adopter 
perceives the need for the innovation, one is unlikely to adopt.  Therefore the perceived 
need must occur before the innovation will be adopted.  
Innovativeness.  According to Rogers (2003), innovativeness is the degree to 
which an individual will adopt an innovation as compared to other members in their 
society.  Therefore an individual‟s innovativeness influences their rate of adoption of an 
innovation. 
Norms of society (Work environment). Rogers (2003) defined the norms of a 
society as the behavioral patterns of its members.  Therefore, behavioral patterns will be 
specific to the work environment of the particular society.  According to Jenkins (1999), 
no relationship was found between work environment including type of workplace, 
length of time within specific work environment, hours worked and the adoption of 
innovation.  
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Ruralality.  Rogers (2003) revealed that adoption of innovation is based upon 
availability of resources, which was confirmed by a study conducted by Tawari and 
Davies (2009).  However, Jenkins (1999) found no relationship with availability of 
resources and adoption of an innovation.   
Personality variables.  Personality variables are characteristics of the particular 
individual.  Two personality variables, age and educational level, were assessed in prior 
research about diffusion of innovations.  Based on the 4000 diffusion publications that 
Rogers reviewed, inconsistent evidence was found on whether age influenced the 
adoption of new ideas (Rogers, 2003).  Almost half of the studies showed no relationship, 
whereas a few studies showed conflicting results in that some studies revealed younger 
individuals as early adopters whereas other studies showed that older individuals were the 
early adopters.  Based on the current literature review, no studies have revealed a 
relationship between age and adoption of an innovation (Damanpour & Schneider, 2009; 
Ostergaard, Timmermans, & Kristinsson, 2011; Tawari & Davies, 2009).  Moreover, 
according to Rogers, many studies reported a relationship between adoption of innovation 
and more years of formal education.  Recent studies also coincide with Rogers (2003).  
These studies found that more formal education had a positive correlation with adoption 
of innovation (Damanpour & Schneider, 2009; Ostergaard et al., 2011; Tawari & Davies, 
2009).   
For the current study, the variables that were assessed were age, years of 
experience in the oncology setting, education level, certification in oncology, currently 
practicing in oncology field, time since last genomic and pharmacogenomic education, 
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association with a pharmacogenomic testing research site and perceived genomic and 
pharmacogenomic testing knowledge. 
Communication behavior. According to Rogers (2003), mass media channels 
are more effective in generating knowledge about the innovation, whereas interpersonal 
channels are more effective in establishing and altering attitudes towards a new idea.   
Relative advantage.  The relative advantage of an innovation may be in the form 
of economic gain or beneficial to society in some other form.  The costs that are saved 
could be either financial or social, such as exclusion from peer groups (Ram, 1987).  The 
innovation could also improve performance or provide a better solution to a problem.  
According to Rogers (2003), if an innovation has a low relative advantage, adoption will 
be resisted among the potential adopters.   
Compatibility. Compatibility characterizes the consistency with the existing 
values of the adopter, as well as traditional and cultural values of the society.  This 
variable is also linked to the concept of pervasiveness.  Pervasiveness of an innovation is 
the amount to which it necessitates change in behavior of the potential adopter (Ram, 
1987).  Therefore, the higher the degree of pervasiveness equals more behavioral change, 
which leads to resistance to adoption. 
Complexity. The complexity of an innovation is comprised of how easy it is to 
understand the innovation as well as how easy it is to implement (Ram, 1987).  Two 
separate components play a role in comprising the complexity of the innovation.  
Therefore, the easier to understand and implement the innovation, creates less resistance 
to adoption.   
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Trialability. Trialability of an innovation relates to the ability of the innovation to 
be trialed before adoption as well as the ability to trial the innovation in stages (Roger, 
2003).  According to Ram (1987), the less trialability equals more resistance to adoption 
of the innovation.  
Observability. According to Rogers (2003), the rate of adoption increases as the 
innovation becomes more visible to the potential adopters.  Observability was categorized 
as having available pharmacogenomic tests or not. 
Summary 
Additional education about, and the acceptance of pharmacogenomic testing will 
most likely be required before genomically guided therapy can be widely utilized 
(Lanfear & McLeod, 2007).  Nurses could play a critical role in the integration of 
pharmacogenomic testing and genotype-guided therapy into routine practice.  However, 
to do this, nurses must be accepting of and knowledgeable about this type of genomic 
testing and therapy.  Nurses who are knowledgeable about this type of testing and therapy 
will be able to discuss the benefits and limitations of this therapy with their patients.  
Nurses must make opportunities to advance their knowledge in genomics including 
pharmacogenomic testing, because nurses are in an excellent situation to synchronize 
inclusive care for their patients that includes these essential genomic components (Pestka, 
2003). 
In order to be a patient advocate, a nurse should have an adequate knowledge base 
about pharmacogenomic testing as well as accessible resources that may enhance the  
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patient's understanding of this therapy (Prows & Beery, 2008).  Educating nurses about 
pharmacogenomic testing and genotype-guided therapy should ultimately have a huge 
impact on patient's understanding and acceptance of pharmacogenomic testing. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
    
 
 
Chapter III 
Methodology 
The purpose of this study was to identify and test key elements of Rogers‟ 
Diffusion of Innovation theory that play a role in the adoption of pharmacogenomic 
testing into the oncology practice by assessing oncology nurses‟ knowledge, attitudes and 
support for use of pharmacogenomic testing.  In this chapter, the research design, 
population and sample, instruments used to measure variables, the methods used to 
protect human subjects, and the procedures for conducting the study are described. 
Research Design 
Based on the information obtained from the review of literature, a study of the 
knowledge, attitudes, and support of use concerning pharmacogenomic testing in the 
oncology nursing field was pertinent.  In order to assess this knowledge and attitudes, the 
type of design that was implemented was a cross-sectional, descriptive survey design.  A 
cross-sectional design was chosen because it gathers information on a population at one 
point in time (Polit & Beck, 2008). In addition, the feasibility of this study allows for the 
use of this type of design. 
  Furthermore, within a descriptive survey design, the dependent variable(s) is 
measured and then compared within the group, while the independent variable(s) is 
observed as it naturally occurs in the population (Brink & Wood, 1998).  Due to the fact 
that the independent variable is only observed rather than controlled, the independent 
variable is controlled through sample selection (Brink & Wood, 1998).  Therefore, a 
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large, representative sample was utilized (Shadish, Cook, & Campbell, 2002).  Moreover, 
a power analysis was conducted to control the possibility of failing to reject a false null 
hypothesis, (i.e. a Type II error), by guaranteeing power at least 0.8 (Brink & Wood, 
1998).  The statistical program, Statistics Calculator, was utilized to calculate the 
appropriate sample size for sufficient power (Soper, 2012).  A f
2
 was utilized to 
determine the appropriate minimum sample size required to test for significance, which is 
calculated by R
2
/ (1 R
2
).  A medium effect size for R
2
 in the analysis of variance context 
is 0.06 (Green & Salkind, 2005).  Therefore, the f
2
 was set at 0.06.  Using the 
significance level of 0.05, in order to detect a moderate effect size of 0.06, the minimum 
sample size was determined to be 202. 
Setting and Sample 
 Population.  The population addressed in this study were nurses who practice in 
the oncology setting within North Carolina.  The sampling frame included all nurses in 
the state of North Carolina who identified themselves as a nurse with a background in 
oncology through the North Carolina Board of Nursing. The study of oncology nurses 
only in the state of North Carolina was chosen due to the feasibility of this study related 
to easier access to information as well as knowledge of specific medical facilities in the 
state of North Carolina associated with pharmacogenomic testing sites specifically related 
to Tamoxifen.  
 Eligibility criteria.  The eligibility criteria for the sample were currently licensed 
practical nurses or registered nurses in an oncology setting within the state of North 
Carolina. 
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Data Sources and Collection 
The sample was obtained from the North Carolina Board of Nursing.  This 
organization has a list of all nurses that work in North Carolina in an oncology setting.  A 
request form was submitted that included the type of media desired for the contact list 
(e.g., CD-ROM, Excel Spreadsheet), contact information for this investigator, a 
description of how the data would be used, and what data was being requested, such as all 
Registered Nurses (RN) in Wake, Durham and Orange counties (See Appendix A).  For 
this study, a request was submitted for a list of all Licensed Practical Nurses (LPN) and 
RNs within the state of North Carolina who work in the oncology field.  Around two 
thousand seven hundred nurses met the eligibility criteria.  For each of these nurses, their 
mailing address was obtained along with additional data such as type of degree and 
setting of employment.  An invitation to participate was distributed to these nurses via a 
postcard sent to their mailing address.  The postcard had a link to an online survey 
through the survey engine, Survey Monkey, in order for this to be completed with 
anonymity.  A chance to win an i-Pad was offered for those who completed the survey in 
order to provide an incentive for a good response rate.   
Aims  
Based on the literature review, the following research questions were formulated. 
Aim #1 
A. What is the perceived and actual knowledge of oncology nurses in the     
state of North Carolina about basic genomic and pharmacogenomic 
testing? 
B. What attitudes do oncology nursing in the state of North Carolina have  
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     concerning pharmacogenomic testing? 
C. What is the support for use of pharmacogenomic testing in the    
     oncology field throughout the state of North Carolina? 
Aim #2 
What are the relationships between actual knowledge of oncology nurses 
in the state of North Carolina concerning basic genomic and pharmacogenomic 
testing and the variables: prior experience with pharmacogenomic testing, 
innovativeness, perceived need of innovation, work setting, ruralality, 
communication behavior, and personality variables such as age, years of 
experience in the oncology setting, education level, certification in oncology, 
currently practicing in oncology field, time since last genomic and 
pharmacogenomic education, association with a pharmacogenomic testing 
research site and perceived genomic and pharmacogenomic testing knowledge? 
Aim #3 
What are the relationships between attitudes of oncology nurses in the 
state of North Carolina concerning pharmacogenomic testing and the variables: 
relative advantage, compatibility, complexity, trialability, and observability of the 
innovation, actual genomic and pharmacogenomic testing  knowledge, prior 
experience with pharmacogenomic testing, innovativeness, perceived need of 
innovation, work setting, ruralality, communication behavior, and personality 
variables such as age, years of experience in the oncology setting, education level, 
certification in oncology, currently practicing in oncology field, time since last 
genomic and pharmacogenomic education, association with a pharmacogenomic 
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testing research site and perceived genomic and pharmacogenomic testing 
knowledge? 
Aim #4 
What are the relationships between the support for use of 
pharmacogenomic testing in the oncology field and the following variables: actual 
genomic and pharmacogenomic testing knowledge, overall attitudes towards 
pharmacogenomic testing, attitudes specifically related to Tamoxifen, age, years 
of experience in the oncology setting, education level, certification in oncology, 
currently practicing in oncology field, time since last genomic and 
pharmacogenomic education, association with a pharmacogenomic testing 
research site and perceived genomic and pharmacogenomic testing knowledge?  
Measurement of Variables  
Several concepts related to demographics were measured, including age, years of 
experience in the oncology setting, education level, certification in oncology, currently 
practicing in oncology field, time since last genomic and pharmacogenomic education, 
association with a pharmacogenomic testing research site, prior experience with 
pharmacogenomic testing, perceived need of innovation, innovativeness, work setting, 
ruralality, association with a pharmacogenomic testing research site. Additionally, other 
concepts that were assessed included basic genomic knowledge and pharmacogenomic 
knowledge as well as perceived knowledge of genomics and pharmacogenomic testing.  
Concepts related to favorability of the innovation such as relative advantage, 
compatibility, complexity, trialability, and observability were also measured. Finally, 
overall attitudes toward pharmacogenomic testing, and attitudes related specifically to 
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pharmacogenomic testing for Tamoxifen, as well as the concept of support for use of 
pharmacogenomic testing within the oncology field were assessed.  These variables are 
highlighted in Table 1. 
Knowledge is defined as the information gained through education or practice.  
Basic genetics is defined as the area of study related to heredity and the variation in 
inherited characteristics (“Genetics”, 2011). Basic genetics knowledge was 
operationalized as the number of basic genetic questions correctly answered.  
Pharmacogenomic testing is defined as the study of the interaction of genomics and 
pharmacotherapy in which genomic testing is used to guide a patient's drug therapy 
(Foley & Quigley, 2010).  Pharmacogenomic testing knowledge was operationalized as 
the number of pharmacogenomic testing questions answered correctly. 
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Antecedents to knowledge within Rogers‟ Innovation of Diffusion framework are  
prior experience, perceived need of innovation, innovativeness, work environment, 
ruralality, personality variables such as age and education level, and communication 
behavior.  Prior experience is defined as the previous awareness of pharmacogenomic 
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testing. This concept was operationalized by whether or not the respondent had heard of 
the term pharmacogenomic testing prior to taking this survey and whether 
pharmacogenomic testing was available at their place of work.  Perceived need of 
innovation was defined as the respondent‟s feelings of whether this innovation would be 
of benefit.  This concept was operationalized by whether or not the individual felt that 
pharmacogenomic testing would be useful in the oncology setting.  Innovativeness was 
defined as the degree to which an individual adopts new ideas as compared to other 
members of their social system.  Innovativeness was operationalized by whether the 
respondent was an innovator, early adopter, early majority, late majority, or laggard, as 
evidenced by their score on the Innovativeness Scale.  Norms of society or work 
environment were defined as the behavioral patterns of the society.  This variable was 
operationalized by the specific type of workplace the nurse worked at (e.g. inpatient 
oncology unit, ambulatory care/outpatient center, hospice/palliative care, etc.).  Ruralality 
was defined as the location of the respondent‟s workplace.  This variable was 
operationalized as the respondent‟s response to working in either a rural or urban setting.  
Personality variables were measured as well (e.g. age, educational level, certification in 
oncology, currently practicing, etc.). Certification in oncology was defined as a nurse 
who is certified by a credentialing organization in the oncology field.  This variable was 
operationalized by whether the nurse held one or more of the seven oncology nursing 
certifications as governed by the Oncology Nursing Certification Corporation.  
Association with a pharmacogenomic testing research site was defined as the affiliation 
with a facility that was a pharmacogenomic testing center.  This variable was 
operationalized by whether the respondent worked at one of the facilities that has been a 
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part of the Tamoxifen pharmacogenomic testing study.  Finally, communication behavior 
was defined as the process by which an individual receives up-to-date information.  This 
concept was operationalized by the mode of media/communication one receives 
information. 
 Attitude was defined as a favorable or unfavorable position about the innovation.  
Overall attitude was operationalized by the number of favorable responses towards use of 
pharmacogenomic testing in general and whether the respondent believed that 
pharmacogenomic testing should be utilized in nursing care.  Attitude specifically related 
to pharmacogenomic testing within the oncology field was operationalized by the number 
of favorable responses towards pharmacogenomic testing.  In combination with attitude, 
the favorability of the innovation was measured by assessing relative advantage, 
compatibility, complexity, trialability, and observability.  Relative advantage was the 
perception that the innovation was better than the current treatment.  This concept was 
operationalized by whether the respondent believed pharmacogenomic testing was 
beneficial for the field of oncology.  Compatibility was the degree to which the 
innovation coexists with the individual‟s existing values, past experiences, and needs.   
Compatibility was operationalized by whether the respondent believed that nurses should 
incorporate pharmacogenomic testing into their practice.  Complexity of the innovation 
was defined as is the degree of difficulty to comprehend.  This concept was 
operationalized by whether the respondents believed that pharmacogenomic testing was 
hard to understand. Trialability is the ability of the innovation to be incorporated into 
practice on a trial basis.  This concept was operationalized by whether the respondent 
believed that pharmacogenomic testing could be adjusted to work better for their type of 
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work setting.  Finally, observability was defined as the degree to which the innovation 
was visible to the individuals.  This concept was operationalized by whether or not the 
individual used or observed pharmacogenomic testing in their place of work.  Finally, 
support for use of pharmacogenomic testing was defined as the degree to which 
pharmacogenomic testing was utilized.  This concept was operationalized by the degree 
to which the respondent used pharmacogenomic testing information in their practice.  
Instruments  
 Knowledge, Attitude, and Support for Use Questionnaire-Pharmacogenomic 
Testing (KAQ-PGx).  The measure that was utilized to assess these concepts was a 
modified version of Van Riper et al.‟s (2012) Knowledge and Attitude Questionnaire 
about Pharmacogenomic testing (KAQ-PGx).  The original questionnaire was developed 
by a team of experts from the University of North Carolina (UNC) Center for Genomics 
and Society and the UNC Institute of Pharmacogenomics and Individualized Therapy 
(Roederer et al, 2012).  This questionnaire assesses knowledge concerning 
pharmacogenomic testing as well as addressing areas of concern that were expressed 
throughout existing literature.  The questionnaire was evaluated by an interdisciplinary 
group, including nurses, physicians, and pharmacists, who were knowledgeable about 
pharmacogenomic testing.  Then a pilot study was conducted by testing five clinicians 
prior to data collection.  The original survey was comprised of: six background 
information questions, two questions concerning overall perceptions of knowledge 
regarding genomics and pharmacogenomic testing, ten basic knowledge questions (five 
about genomics and five about pharmacogenomics), eight questions concerning attitudes 
about pharmacogenomic testing (four about pharmacogenomic testing in general and four 
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focusing on pharmacogenomic testing to guide warfarin therapy), four questions for 
clinicians with prescriptive privileges, and two questions to assess interest in future 
continuing education courses regarding pharmacogenomic testing.  The University of 
North Carolina at Chapel Hill Office of Human Research Ethics determined that the 
Institutional Review Board approval was not mandatory because responses to the 
questionnaire were anonymous (Roederer et al., 2012). 
A team of experts on pharmacogenomic testing knowledge and nursing care 
evaluated and modified the revised version to establish content validity.  The modified 
version included nine additional demographic questions that specifically relate to 
oncology nurses.  Also five questions were added to the background of 
genomics/pharmacogenomics section that specifically relate to nursing.  Additionally, a 
brief summary of pharmacogenomic testing was included within the survey.  Moreover, a 
question regarding their communication behavior was added to the final section. Finally, 
the section of attitudes regarding pharmacogenomic testing for Warfarin was deleted due 
to the fact that oncology medications replaced these items, which related more closely 
with oncology nursing.  
Additionally, ten cognitive interviews were conducted with inpatient and 
outpatient oncology nurses in order to ascertain the validity of the 43 KAQ-PGx items 
and directions. A coding system was developed for each category for their responses.  
Based on these interviews, the following changes were made: 35 of the 43 items were 
interpreted as intended and were unchanged; 6 items were revised; 2 items were deleted; 
and 9 items were added.  In addition, the informational paragraph within the 
questionnaire was revised.  
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Once the cognitive interviews were completed and modifications made, five 
oncology nurses pilot tested the questionnaire to determine the need for additional 
revisions and as well as to determine approximate length of time required for completion 
of questionnaire. 
The finalized survey includes a total of 52 items: 11 demographic questions, two 
questions assessing background in genomic and pharmacogenomic testing education,  
two questions that assesses overall perceptions of understanding about genomics and 
pharmacogenomic testing, four questions designed to assess the availability and 
utilization of pharmacogenomic testing information in their place of work, five basic 
knowledge questions about genomics, five knowledge questions about  
pharmacogenomic testing, eight questions regarding overall attitudes about 
pharmacogenomic testing, six questions focused on attitudes related to pharmacogenomic 
testing used within the oncology field, five questions pertaining to prescriptive privileges, 
three questions about the clinicians‟ interest in future educational offerings about 
pharmacogenomic testing, and an open-ended question addressing any additional 
comments or concerns of the clinicians. In addition, an educational summary of 
pharmacogenomic testing was incorporated into the questionnaire (See Appendix B). 
Innovativeness Scale (IS).  As previously stated, innovativeness was defined as 
the degree to which an individual adopts new ideas as compared to other members within 
their society.  The Innovativeness Scale developed by Hurt, Joseph, and Cook (1977) was 
utilized to measure innovativeness.  This scale has construct validity due to the similarity 
between the outcomes and prior publication of Rogers‟ and Shoemaker‟s adopter 
category distribution (Hurt et al., 1977).  Additionally, the scale had a Cronbach‟s alpha 
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of 0.94 (Hurt et al., 1977).    Twenty questions comprise this survey that assesses how an 
individual responds to their environment.  The score was calculated to determine which 
type of adopter the individual is categorized (e.g. Innovator, Early Majority, etc.).  
Each individual‟s innovativeness score was calculated per the published 
guidelines (Hurt et al., 1977) (See Appendix C).  In step 1, responses to questions 4, 6, 7, 
10, 13, 15, 17, and 20 were summed together.  Then step 2 consisted of summing 
together the responses from questions 1, 2, 3, 5, 8, 9, 11, 12, 14 16, 18, and 19.  Finally, 
in the final step the following formula was used: 42 + total score from step 2 – total score 
from step 1 (Hurt et al., 1977).  Each question utilized a five-point Likert scale with 
Strongly Disagree coded as 1 to Strongly Agree coded as 5.  Each respondent was then 
classified as an Innovator, Early Adopter, Early Majority, Late Majority, or 
Traditionalists based on their scores, and coded 5, 4, 3, 2, and 1, respectively. Scores 
above 80 were classified as Innovators, scores between 69 and 80 were classified as Early 
Adopters, scores between 57 and 68 were Early Majority, scores between 46-56 were 
Late Majority, and scores below 46 were considered Traditionalists (Hurt et al., 1977). 
Nursing Practice Questionnaire-Pharmacogenomic Testing (NPQ-PGx). The 
Nursing Practice Questionnaire was originally developed by Brett in 1987 to measure 
nurses‟ adoption of research findings.  Rogers‟ Diffusion of Innovation framework was 
used to guide the development of this instrument.  Content validity was established prior 
to pilot testing with a total of 25 graduate nursing students.  The results established 
reliability of 0.82, with test-retest reliability of 0.83 (Brett, 1987).   
 The questionnaire included six questions that assess degree of adoption of an 
innovation. Four questions assess the knowledge phase, one measures the attitude phase, 
    
 
44 
and one assesses the support for use phase.  If one answers positively to any of the first 
four questions they are at least within the knowledge phase.  If the respondent answers 
positively to the fifth question, they have a positive attitude towards the innovation.  
Finally, the final questions assess whether they have never, sometimes, or always use the 
innovation, which measured their support for use of the innovation.  This questionnaire 
was scored by assigning a one to a positive answer to having ever heard of the term 
pharmacogenomics, assigning a one to a positive answer to whether a nurse should use 
this in their nursing practice, and finally a zero was assigned to an answer that 
pharmacogenomic testing information was never used in their nursing care, a one if they 
sometimes use this, and a two if they always use this in their nursing care.  Therefore, a 
maximum score of four could be achieved.  Respondents with a score of 0 are in the 
unaware stage, a score of 1 are in the aware stage, 2 are in the persuasion stage, 3 or 
greater are in the adoption stage (Brett, 1987).  This questionnaire was utilized to assess 
all three stages of Rogers‟ Diffusion of Innovation that is focused upon in this study. 
Protection of Human Subjects 
 The study proposal and informed consents were submitted to the University of 
North Carolina at Chapel Hill Office of Human Research Ethics for review and approval 
before implementation of the study.  All participants were asked to sign the informed 
consent and were assigned a number for confidentiality (See Appendix D).  The on-line 
survey was available on Survey Monkey under a professional gold account.  This account 
utilizes Secure Sockets Layer (SSL) encryption, which is a 128 bit encryption.  This 
account sends encrypted links to research participants, in which the link and survey pages 
are secured by Verisign, and then submitted to a secured account.  Additionally, the 
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collected data was downloaded over a secure channel.  Furthermore, the respondents IP 
addresses were not stored in the survey results. 
Statistical Analyses 
 Univariate statistics were conducted for all demographic variables, including 
ranges, means, medians, and standard deviations for continuous variables and frequencies 
and percents for categorical variables.  To address part A of Aim #1, the total score for 
the basic genomic knowledge questions, the total score for the pharmacogenomic 
knowledge questions, and the combination of these total scores were calculated for each 
respondent.  Also the total score for overall attitude, attitudes specifically related to 
Tamoxifen, and the total score for support for use of pharmacogenomic testing were 
calculated to address parts B and C of Aim #1.  Finally, Cronbach‟s alpha was used to 
measure the internal consistency of these totals.  In addition, summary statistics were 
calculated as well as the formation of box plots to assess results. 
To address knowledge in Aim #2, a contingency table was generated for each 
knowledge item in the questionnaire and each of these categorical variables: age, prior 
experience with pharmacogenomic testing, innovativeness, perceived need of innovation, 
ruralality, communication behavior, educational level, certification in oncology, currently 
practicing in oncology field, association with a pharmacogenomic testing research site, 
and perceived genomic and pharmacogenomic testing knowledge.  A Pearson‟s chi 
square test was utilized to determine whether the distribution of the categorical variables 
differ from one another.  Therefore if contingency was found among the categorical 
variables, then they are not independent of one another.  Furthermore, if no contingency 
was found among the categorical variables, then they are independent of one another and 
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there is not enough evidence to reject the null hypothesis. The null hypotheses to be 
considered were: 
H0: Age, prior experience with pharmacogenomic testing, years of experience in 
      the oncology setting, innovativeness, perceived need of innovation,   
      ruralality, communication behavior, educational level,  
      certification in oncology, currently practicing in oncology field, work  
      environment, association with a pharmacogenomic testing research site are  
      independent of perceived genomic and of pharmacogenomic testing  
      knowledge considering one variable at a time. 
A one-way analysis of variance (ANOVA) was conducted relating the total 
number of correct responses on genomic knowledge, on pharmacogenomic testing 
knowledge and on the combination of these questions to each predictor variable: age, 
prior experience with pharmacogenomic testing, years of experience in the oncology 
setting, innovativeness, perceived need of innovation, ruralality, communication 
behavior, educational level, certification in oncology, currently practicing in oncology 
field, work environment, association with a pharmacogenomic testing research site, and 
perceived genomic and pharmacogenomic testing knowledge.  A power analysis was 
conducted to determine the minimum required sample size to achieve statistical 
significance in order to perform the ANOVA, which can be found in the research design 
section.  This statistical test determined whether the total score of a set of knowledge 
questions was significantly different within levels for each of the predictor variables.  The 
null hypothesis tested was: 
H0:  No difference in the knowledge mean across the different levels of each  
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       predictor variable.   
Once the analyses were conducted, a post hoc analysis was conducted for all cases with a 
significant F value to determine which levels of the associated predictor were similar in 
mean knowledge and they were combined.  
Finally, regression models were generated for the totals of the basic genomic 
knowledge questions, the pharmacogenomic testing knowledge questions, and the 
combination of these knowledge questions.  The predictor variables were comprised of 
the variables identified from the one-way ANOVA. Only predictors that had a significant 
one-way ANOVA F test values set at a p<0.05 were utilized and coded as appropriately 
defined indicator variables.  Multicollinearity was assessed prior to performing regression 
models to determine whether two or more predictor variables were highly correlated.   
Variable selection methods were conducted to determine which combination of 
variables were jointly significant predictors of each outcome variable.  Initially, a forward 
selection was conducted.  The initial model included no variables and then each variable 
was chosen one by one and added to the model until no benefit was found with each 
additional variable added.  Then a backward elimination was conducted.  Finally, 
stepwise selection was conducted in which variables were added and removed from the 
model to obtain the best fit for each outcome variable.  If different models were generated 
from the variable selection procedures, then the Akaike Information Criterion (AIC), 
Bayesian information criterion (BIC), and the predicted residual sum of squares (PRESS) 
were utilized to compare the alternative models and select the most appropriate model. 
In addition to knowledge, respondents were asked thirteen questions regarding 
their attitudes regarding pharmacogenomic testing.  Seven questions assessed the 
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respondents‟ attitude towards pharmacogenomic testing in general and six questions 
assessed their attitude towards pharmacogenomic testing specifically related to the 
oncology field.  The answers to these questions were coded for positive attitudes or 
negative attitudes toward the specific topic.  Six questions utilized a Likert scale and had 
a range from 1-4 with 4 being non-favorable. Additionally, seven questions utilized a 
yes/no response, in which were coded as 1 for favorable responses and 2 for non-
favorable responses.  Questions 69-71 were reverse coded so that larger values for all the 
questions corresponded to a more negative attitude. Therefore the higher the score, the 
more negative the attitude.  The possible range for general attitude towards 
pharmacogenomic testing was 7-20 due to the fact that some questions utilized a Likert 
scale and others utilized a yes/no response.  The possible range for attitude toward 
pharmacogenomic testing related to oncology was 6-18.  Finally the possible range for 
overall attitude was 13-38. 
The same kinds of statistical analyzes as conducted for Aim #2 were conducted 
for Aim #3 but using attitude variables as outcomes (that is, contingency table, one-way 
ANOVA, and regression analyses).  Aim #3 null hypotheses included: 
H0:  No difference in the overall attitude or attitude specifically related to  
       Tamoxifen mean score across the different levels of each variable. 
H0: The knowledge of the respondents is independent of the overall attitude about   
       pharmacogenomic testing as well as the attitude specifically related to  
       pharmacogenomic testing of Tamoxifen. 
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The same kinds of statistical analyzes as conducted for Aim #2 were conducted 
for Aim #4 but using support for use of pharmacogenomic testing variable as the 
outcome.  The null hypotheses for Aim #4 were: 
H0:  No difference in the support for use mean score across the different levels of  
        each variable. 
 H0: The knowledge of the respondents is independent of the support for use of  
        pharmacogenomic testing. 
H0: The overall attitude and attitude specifically related to Tamoxifen of the  
       respondents is independent of the support for use of pharmacogenomic  
       testing. 
Finally, regression models were created for the overall attitude scores, attitudes 
specifically related to Tamoxifen, and support of use of pharmacogenomic testing. 
 The assumptions that underlie linear regression are that there are linear 
relationships between the dependent and independent variables, independence of errors in 
which there is no serial correlation, constant variance in errors, and a normal distribution 
of errors and so symmetrical without outliers.  Residual analyses were conducted to 
assess whether results for generated models are reasonably considered to satisfy 
underlying assumptions.  When this was the case, the residuals appeared to be random 
without asymmetry and outliers as well as with constant spread.  Possible asymmetry was 
addressed with transformations. Outliers were addressed with sensitivity analyses to 
assess whether the presence of those outliers had an influence on conclusions or not.   
The statistical package, SAS 9.2 was used to perform all quantitative analyzes. 
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Summary 
This chapter is a summary of the methodological approach that was utilized for 
this research study to test key elements of Rogers‟ Diffusion of Innovation theory in 
order to assess oncology nurses‟ knowledge, attitudes and support for use of 
pharmacogenomic testing.   
 The design of the study was a descriptive survey design to obtain information 
relevant to the concepts found within the literature.  A postcard was mailed to the entire 
population provided by the North Carolina Board of Nursing.  The postcard included a 
link to the online questionnaire.  Data collection methods and statistical analyses were 
described. 
 
 
 
    
 
 
Chapter IV 
Results 
 This chapter reports the results from this study including a description of the 
findings and statistical analyses performed on the data. 
Sample Demographics 
 The sample was obtained from the North Carolina Board of Nursing.  The 
population included 2705 oncology nurses in which a total of 386 subjects started the 
online survey representing a 14.3% response rate.  Out of the surveys that were started, 
368 were used in this data analysis; the other 16 surveys were not used because more than 
half of the items were unanswered.  
 Demographic data was collected on all participants (see Table 2 which includes 
the total number of available responses for each variable).  Each respondent was asked to 
provide their age, highest degree obtained, whether they have a certification in oncology, 
and if so, what type, whether they are currently practicing as an oncology nurse, length of 
time working in oncology, length of time since working in oncology, if not currently 
practicing, whether they work in a rural or urban setting, type of oncology setting, and 
communication behavior. 
 The majority of the respondents (31%) were between the ages of 50-59 years.  In 
addition, almost 46% of the respondents had a Bachelor‟s degree as their highest degree 
obtained, followed by 26.6% with an Associate‟s degree.  Over 37% of the participants 
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worked in an ambulatory or outpatient oncology setting and 36.8% worked in an inpatient 
oncology setting.    
Over 90% of the participants are currently working as an oncology nurse and 47% 
of these have been working in oncology for over 20 years.  Additionally, 55% of all the 
respondents have a certification in oncology, in which the Oncology Certified Nurse was 
the most commonly type of certification acquired.  Furthermore, 76.9% of the nurses 
identified themselves as working in an urban setting.   
Table 2: Demographic Variables n (%) 
Age (years) 
18-29  
30-39 
40-49 
50-59 
60-69 
70 or greater 
Total 
 
40      (10.9) 
86      (23.4) 
99      (26.9) 
114    (31) 
28      (7.6) 
1        (0.3) 
                         368      
Degree 
LPN 
Diploma 
AD 
BSN 
MSN 
Nurse Practitioner 
DNP 
PhD 
Total 
 
4        (1.1) 
25      (6.8) 
98      (26.6) 
167    (45.4) 
44      (12) 
3        (0.8) 
2        (0.5) 
4        (1.1) 
347 
Certification in Oncology 
Yes 
Type 
OCN
a
 
CPON
b
 
CPHON
c
 
AOCN
d
 
CBCN
e
 
AOCNP
f
 
AOCNS
g
 
 
No 
Total 
 
202 (54.9) 
 
178    (88) 
0 
1 (0.5) 
8        (4) 
4        (2) 
9        (4.5) 
2        (1) 
 
166    (45.1) 
368 
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Currently Practicing in Oncology 
Yes 
Length of Time Working 
(yrs)  
Over 30 
25-29 
20-24 
15-19 
10-14 
5-9 
1-4 
Under 1 
 
No 
Length of Time Since 
Working (yrs) 
 
Under 1 
1-5 
6-10 
11-20 
Over 20 
Total 
 
334 (90.8) 
 
3     (0.9) 
71   (21.3) 
83   (24.9) 
54   (16.2) 
40   (12) 
31   (9.3) 
28   (8.4) 
23   (6.9) 
 
34   (9.2) 
 
 
 
19  (59.4) 
6    (18.8) 
5    (15.6) 
2    (6.3) 
0 
368 
Ruralality 
Rural 
Urban 
Total 
 
77    (23.1) 
257  (76.9) 
334 
Type of Work Setting 
Inpatient Oncology Unit 
Ambulatory /Outpatient Center 
Hospice/Palliative Care 
Pain Management 
Cancer Risk Assessment Center 
Home Health 
University/College Setting 
Physician‟s Office 
Research/Laboratory 
Other 
Total 
 
123  (36.8) 
125  (37.4) 
20    (6.0) 
0       
1      (0.3) 
1      (0.3) 
10    (3.0) 
31    (9.3) 
17    (5.1) 
4      (1.2) 
334 
Communication Behavior 
Utilizes 2 or Less Forms of Media 
Utilizes 3-4 Forms of Media 
Utilizes 5-6 Forms of Media 
Total 
 
196  (53.3) 
150  (40.8) 
22    (6) 
368 
a OCN: Oncology Certified Nurse; b CPON: Certified Pediatric Oncology Nurse; c CPHON: Certified Pediatric Hematology/Oncology 
Certified Nurse ; d AOCN: Advanced Oncology Certified Nurse; e CBCN: Certified Breast Care Nurse; f  AOCNP: Advanced Oncology 
Certified Nurse Practitioner; e AOCNS: Advanced Oncology Clinical Nurse Specialist 
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Pharmacogenomic Testing Utilization 
  Over 69% of the participants revealed that they have heard the term 
pharmacogenomics or pharmacogenetics.  In addition, 54% of the respondents do not 
work at a pharmacogenomic testing research site (Table 3).  Fifty one percent of the 
participants indicated that they were unsure whether pharmacogenomic testing is 
available at their place of employment.  Furthermore, 47.8% of the respondents stated 
that they have cared for a patient who has had a pharmacogenomic test, whereas greater 
than 75% of the nurses stated that they have never educated a patient regarding 
pharmacogenomic testing nor advocated for any of their patients to undergo 
pharmacogenomic testing.  Finally, 62% of the study participants felt that they use 
pharmacogenomic testing information sometimes in their nursing care. 
In addition, the Nursing Practice Questionnaire was also given to the respondents.  
The Cronbach‟s alpha for this scale was 0.59.  The average among this sample was 1.92 
with a standard deviation of 0.95 (Table 4).  Therefore, on average, the respondents are 
within the awareness stage regarding pharmacogenomic testing. 
Statistical Analyses 
Descriptive statistics were performed for Aim #1.  For Aim #2, #3, and #4, both 
descriptive and correlational statistics were performed. 
Aim # 1 Analyses 
For Aim #1, analyses addressed the following research questions, “what is the 
perceived and actual knowledge of oncology nurses in the state of North Carolina about 
basic genomic and pharmacogenomic testing,” “what attitudes do oncology nursing in the 
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Table 3: Pharmacogenomic Testing 
Utilization 
n      (%) 
Ever Cared for Patient who Received a 
Pharmacogenomic Test 
Yes 
No 
Unsure 
Total 
 
 
176  (47.8) 
73    (19.8) 
119  (32.3) 
368 
Ever Educated a Patient about 
Pharmacogenomic Testing 
Yes 
No 
Total 
 
 
85    (23.1) 
283  (76.9) 
368 
Ever Advocated for a Patient to Undergo 
Pharmacogenomic Testing 
Yes 
No 
Total 
 
 
89    (24.2) 
279  (75.8) 
368 
Pharmacogenomic Tests Available 
Yes 
No 
Unsure 
Total 
 
111  (30.2) 
69    (18.8) 
188  (51.1) 
368 
Association with Pharmacogenomic 
Testing Site 
Yes 
No 
Total 
 
 
181  (54.2) 
153  (45.8) 
334 
 
Table 4: Nursing Practice Questionnaire                              n      (%) 
 
Unaware 
Aware 
Persuasion 
Adoption 
     Total 
 
           Mean 
           SD 
           Range 
 
27     (7.3) 
102   (27.7) 
114   (31) 
125   (34) 
368 
 
1.92 
0.95 
0-3 
 
state of North Carolina have concerning pharmacogenomic testing,” and “what is the 
support for use of pharmacogenomic testing in the oncology field throughout the state of 
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North Carolina”?  In addition, there were questions concerning previous knowledge of 
genomics and pharmacogenomics.  Perceived knowledge responses were coded 1-5 for 
poor to excellent, with higher scores indicating better perceived knowledge.  Responses 
for previous knowledge were coded: 1 for yes and 0 for no.   
Fifty-eight percent of the respondents revealed that they have had previous 
genomic education (Table 5).  The majority (59%) of the respondents have had this 
education since 2010. Over 68% of the study participants feel that they have a fair or 
poor understanding of genetics (Figure 3). Additionally, 62.5% of the participants have 
never had any pharmacogenomic education. Seventy two percent of the respondents rated 
their perceived knowledge of pharmacogenomic testing as fair or poor as well (Figure 4). 
Five questions assessed actual genetic knowledge and five questions assessed 
actual pharmacogenomic knowledge.  The possible range for actual genetic knowledge 
and actual pharmacogenomic knowledge was 0-5.  The possible range for total 
knowledge was 0-10.  Additionally, Cronbach‟s alpha was calculated for each scale.   
The basic genomic knowledge scale had an alpha of 0.68 and pharmacogenomic 
knowledge scale had an alpha of 0.67.  The total actual knowledge scale had an alpha of 
0.64. 
The mean actual genomic knowledge score was 2.45 with a standard deviation of 
1.4 (Table 6).  In addition, the mean actual pharmacogenomic score was 2.61 with a 
standard deviation of 1.44.  Finally, the mean total genomic knowledge score was 5.09 
with a standard deviation of 2.43.   
The mean score for attitude towards pharmacogenomic testing in general was 14.1 
with a standard deviation of 3.9 (Table 7).  Furthermore, the mean score for attitude 
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   Figure 3: Perceived Genomic Knowledge 
 
 
 
 
 
 
 
 
 
 
 
   Figure 4: Perceived Pharmacogenomic Knowledge 
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Table 5: Perceived Knowledge                             n      (%) 
Previous Genomic Education 
Yes 
Last Course Taken 
Since 2010 
2005-2009 
2000-2004 
1990‟s 
1980‟s 
1970‟s 
 
No 
Total 
 
214  (58.2) 
 
88    (58.7) 
33    (22) 
13    (8.7) 
7      (4.7) 
4      (2.7) 
5      (3.3) 
 
154  (41.8) 
368 
 
Perceived Genomic Knowledge 
Poor 
Fair 
Good 
Very Good 
Excellent 
Total 
 
44    (12) 
208  (56.5) 
96    (26.1) 
18    (4.9) 
2      (0.5) 
368 
Previous Pharmacogenomic Education 
Yes 
No 
Total 
 
138  (37.5) 
230  (62.5) 
368 
Perceived Pharmacogenomic Knowledge 
Poor 
Fair 
Good 
Very Good 
Excellent 
Total 
 
91    (24.7) 
174  (47.3) 
75    (20.4) 
25    (6.8) 
3      (0.8) 
368 
 
towards pharmacogenomic testing related to oncology was 9.2 with a standard deviation 
of 2.9.  Finally, the overall attitude towards pharmacogenomic testing produced a mean 
score of 23.3 and a standard deviation of 6.1.  The general attitude scale had an alpha of 
0.69, whereas the attitude scaled related to oncology had an alpha of 0.76.  Finally, the 
overall attitude scale had an alpha of 0.70.  Each individual attitude question is addressed 
in Table 8 with frequency and percentages. 
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Table 6: Actual Genomic Knowledge 
n=362-368 
Correct (%) 
 
Item 1 
Item 2 
Item 3 
Item 4 
Item 5 
 
Basic Genomic Score 
Mean 
Range 
SD 
 
Item 6 
Item 7 
Item 8 
Item 9 
Item 10 
 
Pharmacogenomic Score 
Mean 
Range 
SD 
 
Total Score 
Mean 
Range 
SD 
 
149  (40.5) 
217  (59) 
157  (42.7) 
112  (30.4) 
272  (73.9) 
 
 
2.45 
0-5 
1.4 
 
308  (83.7) 
192  (52.2) 
72    (19.6) 
208  (56.5) 
187  (50.8) 
 
 
2.61 
0-5 
1.44 
 
 
5.09 
0-10 
2.43 
 
Lastly, study participants were asked one question related to support for use of 
pharmacogenomic testing.  The range for this question was 0-2.  The respondents were 
asked how often they utilize pharmacogenomic testing information in their nursing care.   
The three choices were „never‟, „sometimes‟, and „always‟ which were coded 0, 1, and 2, 
respectively.  The mean score for the support for use of pharmacogenomic testing was 
1.33 with a standard deviation of 0.52 (Table 9). 
Summary. Oncology nurses who participated in this study felt that they do not 
have fair knowledge of both genomics and pharmacogenomic testing based on their 
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Table 7: Attitude Scales  
General Attitude 
Mean 
Range 
SD 
 
Attitude toward Pharmacogenomics 
Related to Oncology 
Mean 
Range 
SD 
 
Overall Attitude 
Mean 
Range 
SD 
 
14.1 
7-20 
3.9 
 
 
 
9.2 
6-18 
2.9 
 
 
23.3 
13-38 
6.1 
 
perceived genomic knowledge. The results revealed that oncology nurses‟ actual 
understanding of genomics was about the same as their own perception of their 
knowledge based on the fact that they answered about half of the genomic and 
pharmacogenomic testing questions correctly.   
In general, attitudes towards pharmacogenomic testing were overall positive.  
Attitudes specifically related to oncology had a more favorable response than attitudes 
towards pharmacogenomic testing in general.  Furthermore, the majority of the 
participants revealed that they utilize pharmacogenomic testing information sometimes to 
always in their nursing care.  A minimal amount of oncology nurses stated that they never 
utilize this type of information in their nursing care. 
Aim #2 Analyses 
Aim #2 analyses addressed the following research question, “what are the 
relationships between actual knowledge of oncology nurses in the state of North Carolina 
concerning basic genomic and pharmacogenomic testing and the variables: prior  
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Table 8:  Attitude Scale Items n   (%) 
Perceived Need of Pharmacogenomics 
Yes 
No 
Total 
 
326 (89.1) 
40   (10.9) 
366 
Believe in Education Patients about 
Pharmacogenomics 
Yes 
No 
Total 
 
 
278  (76.6) 
85    (23.4) 
363 
Fear Unauthorized Access 
Not Concerned 
Somewhat Concerned 
Concerned 
Very Concerned 
Total 
 
122  (33.4) 
150  (41) 
64    (17.4) 
29    (8.2) 
365 
Fear Discrimination 
Not Concerned 
Somewhat Concerned 
Concerned 
Very Concerned 
Total 
 
85    (23.1) 
137  (37.2) 
87    (23.6) 
59    (16) 
368 
Fear Family will be Affected 
Not Concerned 
Somewhat Concerned 
Concerned 
Very Concerned 
Total 
 
82    (22.3) 
154  (41.9) 
80    (21.7) 
52    (14.1) 
368 
Trust 
Strongly Distrust 
Distrust 
Trust 
Strongly Trust 
Total 
 
7     (1.9) 
108 (29.4) 
194 (52.7) 
59   (16) 
368 
Decrease Adverse Drug Events 
Yes 
No 
Unsure 
Total 
 
296  (80.3) 
12    (3.3) 
60    (16.3) 
368 
Decrease Costs of Prescription Medicine 
Yes 
No 
Unsure 
Total 
 
116  (31.5) 
129  (35.1) 
123  (33.4) 
368 
Relative Advantage 
Yes 
No 
Total 
 
346  (95.4) 
17    (4.6) 
363 
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Believe Tamoxifen is Genetically Based 
Yes 
No 
Unsure 
Total 
 
233  (63.3) 
7      (1.9) 
128  (34.8) 
368 
Believe Tumor-Profiling is Useful 
Yes 
No 
Unsure 
Total 
 
311   (84.5) 
5       (1.4) 
52     (14.1) 
368 
Comfortable Using Pharmacogenomics  
On Your Patient 
Not Comfortable 
Somewhat Comfortable 
Comfortable 
Very Comfortable 
Total 
On Yourself 
Not Comfortable 
Somewhat Comfortable 
Comfortable 
Very Comfortable 
Total 
 
 
20    (5.4) 
75    (20.7) 
175  (48.4) 
92    (25.5) 
362 
 
14    (3.8) 
58    (16) 
138  (38) 
152 (42) 
362 
 
Table 9: Support for Use n   (%) 
Support for Use 
 
Never Use 
Sometimes Use 
Always Use 
Total 
 
Mean 
Range 
SD 
 
 
 
231 (63.6) 
132 (36.4) 
0 (0) 
363 
 
1.33 
0-2 
0.52 
 
 
experience with pharmacogenomic testing, innovativeness, perceived need of innovation, 
work setting, ruralality, communication behavior, and personality variables such as age, 
years of experience in the oncology setting, education level, certification in oncology, 
currently practicing in oncology field, time since last genetic and pharmacogenomic 
education, association with a pharmacogenomic testing research site and perceived 
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genetic and pharmacogenomic testing knowledge”?  Before any statistical analysis could 
be performed, the innovativeness score for each respondent was first calculated (Table 
10).  The Cronbach‟s alpha for this scale was 0.73.  Additionally, the frequency and 
percentages of each innovator type for this sample was calculated (Table 10).  This study 
sample consisted of 17.4% innovators, 47.8% early adopters, 28.8% of early majority, 
5.4% late majority, and 0.5% as traditionalists.  Figure 5 shows the rate of adoption and 
normal percentages for each innovator type. 
Table 10: Innovativeness n      (%) 
Innovator Type 
Innovator 
Early Adopter 
Early Majority 
Late Majority 
Traditionalists 
Total 
 
Innovativeness Score 
Mean 
Range 
SD 
 
64    (17.4) 
176  (47.8) 
106  (28.8) 
20    (5.4) 
2      (0.5) 
368 
 
 
71.95 
37-92 
9.2 
 
                    
 
Figure 5: Diffusion of Innovation according to Rogers (2003).  Blue line indicates the percentages of 
categories that the group needs to have successful adoption of an innovation. Yellow line indicates the 
adoption rate of the innovation. 
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Secondly, a contingency table was calculated for each categorical variable and 
each item on the genomic knowledge scale. A Pearson‟s chi square test was calculated 
for each categorical variable to determine whether the distribution of each item differed 
over the levels of each categorical variable.  The contingency table revealed that 
responses to item #41 (17.06, p=0.0044) and item #48 (12.09, p=0.0336) changed with 
age.  Responses to item #50 (4.39, p=0.0361) changed with prior experience and 
responses to item #44 (15.45, p=0.0039) changed with innovativeness.  Responses to 
item #50 (25.94, p=0.0011) changed with education level.  Responses to items #43, 45, 
46, 49 and 50 (8.57, p=0.0034; 7.79, p=0.0053; 9.62, p=0.0019; 6.25, p=0.0124; 20.02, 
p<0.0001) changed with certification in oncology nursing. Responses to item #50 (30.89, 
p=0.0001) changed with type of work setting.  Additionally, responses to items #42, 43, 
44, 45, 47, 48, and 50 (26.64, p<0.0001; 14.49, p=0.0059; 11.91, p=0.0181; 12.12, 
p=0.0165; 13.61, p=0.0086; 17.35, p=0.0017; 25.21, p <0.0001) changed with perceived 
genomic knowledge.  Finally, responses to items # 42, 43, 45, 46, 48, and 50 (10.06, 
p=0.0395; 19.33, p=0.0007; 11.36, p=0.0228; 12.95, p=0.0115; 10.77, p=0.0293; 25.26, 
p<0.0001) changed with perceived pharmacogenomic knowledge. 
Furthermore, a one-way ANOVA was conducted to determine whether the total score for 
the knowledge questions differ significantly within each of the variables (Table 11).  
There was a significant effect of perceived basic genomic knowledge on the total actual 
knowledge score [F(4, 328)=10.97, p<0.0001].  A Bonferroni post-hoc test was 
completed and the categories of poor and fair perceived genomic knowledge were 
combined due to their similarity.  Also there was a significant effect of previous genomic 
education [F(1, 331)=14.36, p=0.0002] and previous pharmacogenomic education [F(1,  
 65 
 
Table 11: ANOVA-
Actual Overall 
Genomic Knowledge 
β df1, df2  F p 
Age  5, 327 2.22 0.0673 
Degree  8, 324 0.64 0.7456 
Certification  1, 331 10.02 0.0017 
Yes 0.00    
No -0.68    
Currently Working  1, 331 0 0.9494 
Ruralality  1, 331 0.60 0.0115 
            Rural -0.65    
            Urban 0.00    
Associated with 
Pharmacogenomic 
Research Site 
 1, 331 0.51 0.4749 
Work Setting  7, 325 0.52 0.8208 
Previous Genomic 
Education 
 1, 331 5.94 0.0154 
Yes 0.00    
No -0.44    
Perceived Genomic 
Knowledge 
 4, 328 2.9 0.0224 
            Poor -2.34    
            Fair -1.85    
            Good -0.62    
             Very Good -1.30    
             Excellent 0.00    
Perceived 
Pharmacogenomic 
Knowledge 
 4, 328 0.29 0.8829 
Previous 
Pharmacogenomic 
Education 
 1, 331 9.94 0.0018 
Yes 0.00    
No -0.28    
Available 
Pharmacogenomic Tests 
 2, 330 8.06 0.0004 
            Yes 0.69    
            No 0.33    
           Unsure 0.00    
Prior Experience  2, 330 18.57 <0.0001 
Yes 0.32    
No 0.00    
Perceived Need  1, 331 3.58 0.0594 
*β0: 7.03 
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331)=9.94, p=0.0018] on the total actual knowledge score.  Also availability of 
pharmacogenomic tests [F(2, 330)=8.06, p=0.0004] and prior experience with 
pharmacogenomic testing [F(2, 330]=18.57, p<0.0001] had a significant effect on the 
total actual knowledge score.  Furthermore, there was a significant effect of ruralality on 
total actual knowledge score [F(1, 331)=4.50, p=0.0348].  Finally, there was a significant 
effect of certification on total actual knowledge score [F(1, 331)=10.02, p=0.0017]. 
In addition, a one-way ANOVA was conducted with the dependent variable of 
actual basic genomic knowledge score (Table 12).  There was a significant effect of age 
[F(5, 327)=2.85, p=0.0244], perceived genomic knowledge [F(4, 328)=10.48, p<0.0001], 
previous genomic education [F(1, 331)=5.05, p=0.0253], perceived need of 
pharmacogenomic testing [F(1, 331)=13.04, p<0.0001], prior experience [F(2, 330)=5.38, 
p=0.0209], ruralality [F(1, 331)=5.11, p=0.0246], and whether or not respondent has  
certification in oncology [F(1, 331)=7.57, p=0.0063].  A Bonferroni post-hoc test was 
completed and the categories of poor and fair perceived genomic knowledge were 
combined due to their similarity.  In addition, the age groups of 18-29 and 30-39 were 
combined based on the Bonferroni test as well as 40-49 and 50-59 years.  Finally, a one-
way ANOVA was conducted with the dependent variable of actual pharmacogenomic 
knowledge (Table 13).  There was a significant effect across perceived genomic 
knowledge [F(4, 328)=7.66, p<0.0001], previous genomic education [F(1, 331)=19.08, 
p<0.0001], previous pharmacogenomic education [F(1, 331)=17.09, p<0.0001], prior 
experience [F(2, 330)=24.63, p<0.0001], available pharmacogenomic tests [F(2, 
330)=13.96, p=0.0003], and certification in oncology [F(1, 331)=9.90, p=0.0018].  A 
Bonferroni post-hoc test was completed and the categories of poor and fair perceived 
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Table 12: ANOVA-Basic 
Genomic Knowledge 
β df1, df2 F p 
Age  5, 327 2.85 0.0244 
         18-29 2.76    
         30-39 2.50    
         40-49 2.22    
         50-59 2.05    
         60-69 1.74    
         70 or greater 0.00    
Degree  8, 324 0.39 0.928 
Certification  1, 331 7.57 0.0063 
Yes 0.00    
No -0.34    
Currently Working  1, 331 0.64 0.4239 
Ruralality  1, 331 5.11 0.0246 
  Rural -0.39    
  Urban 0.00    
Associated with 
Pharmacogenomic Research 
Site 
 1, 331 0.75 0.3880 
Work Setting  7, 325 0.43 0.8814 
Previous Genomic Education  1, 331 5.05 0.0253 
Yes 0.00    
No -0.27    
Perceived Genomic Knowledge  4, 328 10.48 <0.0001 
         Poor -1.87    
         Fair -1.33    
         Good -0.72    
          Very Good -0.61    
          Excellent 0.00    
Perceived Pharmacogenomic 
Knowledge 
 4, 328 0.45 0.7744 
Previous Pharmacogenomic 
Education 
 1, 331 3.75 0.0535 
Available Pharmacogenomic 
Tests 
 2, 330 3.02 0.0502 
Prior Experience  2, 330 13.04 <0.0001 
Yes 0.17    
No 0.00    
Perceived Need  1, 331 5.38 0.0209 
Yes 0.12    
No 0.00    
*β0: 1.55 
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Table 13: 
ANOVA-
Pharmacogenomic 
Knowledge 
β df1, df2 F p 
Age  5, 327 1.22 0.3008 
Degree  8, 324 0.93 0.4930 
Certification  1, 331 9.9 0.0018 
Yes 0.00    
No -0.41    
Currently Working  1, 331 1.03 0.3108 
Ruralality  1, 331 1.87 0.1723 
Association with 
Pharmacogenomic 
Research Site 
 1, 331 1.02 0.3122 
Work Setting  7, 325 1.97 0.0593 
Previous Genomic 
Education 
 1, 331 19.08 <0.0001 
Yes 0.00    
No -0.31    
Perceived Genomic 
Knowledge 
 4, 328 7.66 <0.0001 
            Poor -0.63    
            Fair -0.64    
            Good -0.01    
            Very Good -0.87    
            Excellent 0.00    
Perceived 
Pharmacogenomic 
Knowledge 
 4, 328 0.43 0.7868 
Previous 
Pharmacogenomic 
Education 
 1, 331 17.09 <0.0001 
Yes 0.00    
No -0.27    
Available 
Pharmacogenomic 
Tests 
 2, 330 13.96 0.0003 
            Yes 0.47    
            No 0.39    
           Unsure 0.00    
Prior Experience  2, 330 24.63 <0.0001 
Yes 0.17    
No 0.00    
Perceived Need  1, 331 0.71 0.3993 
*β0: 3.31 
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genomic knowledge were combined due to their similarity.  Also multicollinearity was 
not found among any of these variables. 
Finally, regression models were generated for each of the knowledge scores, basic 
genomic knowledge, pharmacogenomic testing knowledge, and the combination of the 
scores. The significant predictors that were found in the one-way ANOVA were utilized 
as indicator variables in the regression models.  A forward regression model was initially 
conducted.  Then a backward elimination was performed.  Finally, a stepwise regression 
model was conducted. 
The forward and stepwise regression model for total genomic knowledge revealed that 
four indicator variables, certification in oncology, prior experience, previous genomic 
education, and perceived genomic knowledge, created a significant model [F=(4, 
363)=20.44, p<0.0001] (Table 14).  However, a backward elimination concluded five 
indicator variables with the addition of the demographic variables [F(5, 362)=17.06, 
p<0.0001].  After both models were compared utilizing AIC, BIC, and PRESS criteria to 
determine the best model, the forward elimination model was found to be the best model 
because it had the lowest AIC, BIC, and PRESS (O‟Meara, 2012). 
A significant model for basic genomic knowledge scores was identified by 
utilizing forward regression modeling to reveal five indicator variables: age, oncology 
certification, perceived genomic knowledge, ruralality, and perceived need [F(6, 
361)=13.85, p<0.0001] (Table 14).  A stepwise regression revealed the same results.  
However, a backward elimination found an additional indicator variable: previous 
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education in genomics [F(7, 360)=12.25, p<0.0001].  The backward elimination model 
was found to be the best model because it had the lowest AIC, BIC, and PRESS. 
Finally, a forward regression technique for pharmacogenomic knowledge scores 
were used and determined that oncology certification, previous genomic education and  
prior experience were significant indicator variables [F(3, 364)=26.55, p<0.0001] (Table 
14).  A backward elimination and stepwise regression identified the same model.  
Residual analyses were completed for all significant models and no outliers were found. 
Summary.  This study revealed that total actual genomic knowledge was 
significantly associated with multiple personality variables including perceived basic 
genomic knowledge, previous genomic education, and certification acquisition, prior 
experience with pharmacogenomic testing as well as ruralality.  Perceived need of 
pharmacogenomic testing, innovativeness, work environment, and communication 
behavior were not significantly associated with the total genomic knowledge score.   
Oncology nurses who had a higher perceived basic genomic knowledge, previous 
genomic and pharmacogenomic education, prior experience with pharmacogenomic 
testing, an oncology certification in nursing, and working in an urban area had a 
significantly higher mean actual knowledge score.  Furthermore, the regression model 
indicated that total genomic knowledge was more accurately predicted by prior 
experience with pharmacogenomic testing and personality variables: certification in 
oncology nursing, perceived genomic knowledge, and previous genomic education.  
Actual basic genomic knowledge was influenced by several factors within the guiding 
framework including ruralality, prior experience, perceived need, and personality 
variables:  age, perceived genomic knowledge, previous genomic education, and  
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Table 14:  
Regression for 
Knowledge 
  
F 
 
R
2
 
 
β 
 
SEβ 
Overall Knowledge Perceived 
Knowledge 
20.44  0.18 0.74 0.17 
Previous Genomic 
Education   
0.63 0.26 
Certification   0.69 0.25 
Prior Experience   0.39 0.14 
Ruralality
1
   - - 
Basic Genomic 
Knowledge 
Perceived 
Knowledge 
12.25 0.19 0.47 0.09 
Certification   0.35 0.14 
Prior Experience   0.31 0.13 
Perceived Need   0.54 0.22 
Age   -0.24 0.06 
Ruralality   0.38 0.17 
Previous Genomic 
Education   
0.25 0.15 
Pharmacogenomic 
Knowledge 
Certification 26.55 0.18 0.46 0.15 
Prior Experience   0.24 0.10 
Previous Genomic 
Education   
0.44 0.16 
1
: Included only in backward elimination  
 
certification attainment in oncology nursing. This study revealed that oncology nurses 
who had a higher perceived basic genomic knowledge score, previous genomic 
education, oncology certification, younger age, worked in an urban area, prior experience 
with pharmacogenomic testing, and perceived need for pharmacogenomic testing had a 
significantly higher total actual basic knowledge score.   
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Furthermore, the regression model indicated that total basic genomic knowledge 
was more accurately predicted by prior experience with pharmacogenomic testing, 
ruralality, perceived need of pharmacogenomic testing, and personality variables: age, 
certification in oncology nursing, perceived genomic knowledge, and previous genomic 
education.   
Actual pharmacogenomic knowledge was influenced by several factors associated 
with the guiding theory.  Prior experience and personality variables of perceived genomic 
knowledge, previous genomic and pharmacogenomic education, and certification 
attainment in oncology nurses significantly influence knowledge of pharmacogenomic 
testing.  Respondents with a higher perceived knowledge, certification in oncology 
nursing, prior experience with pharmacogenomic testing, and previous genomic and 
pharmacogenomic education had a higher total pharmacogenomic knowledge score.  
Moreover, the regression model indicated that total pharmacogenomic knowledge was 
more accurately predicted by the personality variables: certification in oncology nursing, 
perceived genomic knowledge, and previous genomic education.   
Therefore, Aim # 2 was partially supported in addressing which relationships 
were associated with actual knowledge of oncology nurses in the state of North Carolina 
and only a few of the variables successfully predicted the dependent variable of actual 
knowledge. 
Aim # 3 Analyses 
Aim # 3 analyses addressed the following research question, “what are the 
relationships between attitudes of oncology nurses in the state of North Carolina 
concerning pharmacogenomic testing and the variables: relative advantage, compatibility, 
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complexity, trialability, and observability of the innovation, actual genomic and 
pharmacogenomic testing knowledge, prior experience with pharmacogenomic testing, 
innovativeness, perceived need of innovation, work setting, ruralality, communication 
behavior, and personality variables such as age, education level, certification in oncology, 
currently practicing in oncology field, association with a pharmacogenomic testing 
research site and perceived genomic and pharmacogenomic testing knowledge”? 
The same statistical analyses conducted in Aim # 2 were also performed for this 
Aim. A contingency table was calculated for each categorical variable and each item on 
the attitude scale. The contingency table revealed that feeling comfortable utilizing 
pharmacogenomic testing on oneself  was not associated with relative advantage (9.18, 
p=0.0270).  Also perceived usefulness of tumor profiling (97.25, p <0.0001) and belief 
that Tamoxifen is genetically determined (30.76, p<0.0001) were not associated with 
relative advantage.  Also belief that pharmacogenomic testing would decrease cost of 
medications (8.20, p=0.0042) and decrease in adverse drug reactions (73.27, p<0.0001) 
were not associated with relative advantage.  Furthermore, feeling comfortable utilizing 
pharmacogenomic testing on their patient or oneself, perceived usefulness of tumor 
profiling, belief that pharmacogenomic testing would decrease cost of medications and 
decrease in adverse drug reactions (8.09, p=0.0442; 9.49, p=0.0235; 51.31, p<0.0001; 
13.56, p=0.0002; 127.64, p <0.0001 68.10, p<0.0001) were not associated with 
complexity.  Perceived usefulness of tumor profiling, belief that Tamoxifen is genetically 
determined, and belief that oncology is a promising area for pharmacogenomic testing 
(3.90, p=0.0482; 4.90, p= 0.0269; 12.13, p=0.0005) were not associated with prior 
experience. 
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Furthermore, a one-way ANOVA was conducted to determine whether the overall 
attitude differs significantly within each of the variables (Table 15).  There was a 
significant effect of communication behavior [F(2, 365)=6.52, p=0.0017], prior 
experience [F(2, 365)=96.61, p<0.0001], observability of pharmacogenomic testing [F(2, 
365)=4.29, p=0.0146], trialability [F(2, 365)=5.12, p=0.0018], relative advantage [F(1, 
366)=41.45, p<0.0001], and perceived need of pharmacogenomic testing [F(1, 
366)=10.07, p=0.0017] on the total overall attitude score.  A Bonferroni post-hoc test was 
completed and the categories within the communication behavior of greater than three 
modes of communication were combined due to their similarity. Also multicollinearity 
was not found among any of these variables. 
In addition, a one-way ANOVA was conducted with the dependent variable of 
general attitude of pharmacogenomic testing (Table 16).  There was a significant effect of 
highest educational degree obtained [F(8, 359)=2.07, p=0.0383], perceived need of 
pharmacogenomic testing [F(1, 366)=6.45, p=0.0116], prior experience [F(1, 366)=96.61, 
p<0.0001], communication behavior [F(2, 365)=1.21, p=0.0163], trialability [F(2, 
365)=4.84, p=0.0026], and relative advantage [F91, 366)=26.21, p<0.0001].  A 
Bonferroni post-hoc test was completed and the categories within the communication 
behavior of greater than three modes of communication were combined due to their 
similarity.  In addition, the post-hoc analysis determined that the Doctorate of Nursing 
Practice (DNP) and LPN categories had similar general attitude towards 
pharmacogenomic testing.  Finally, a one-way ANOVA was conducted with the 
dependent variable of attitude toward pharmacogenomic testing specifically related to 
oncology (Table 17).  There was a significant effect across previous genomic education  
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Table 15: ANOVA-Overall 
Attitude 
β df1, df2 F p 
Age  5, 362 0.60 0.7023 
Degree  8, 359 1.39 0.1997 
Certification  1, 366 1.47 0.2270 
Currently Working  1, 366 0.02 0.8970 
Ruralality  1, 366 3.11 0.0787 
Associated with 
Pharmacogenomic Research Site 
 1, 366 77.76 0.1053 
Work Setting  7, 360 1.86 0.0661 
Previous Genomic Education  1, 366 1.79 0.1821 
Perceived Genomic Knowledge  4, 363 0.94 0.4387 
Perceived Pharmacogenomic 
Knowledge 
 4, 363 1.17 0.3253 
Previous Pharmacogenomic 
Education 
 1, 366 0.08 0.7787 
Available Pharmacogenomic Tests  2, 365 4.29 0.0146 
Yes -1.97    
No -1.55    
      Unsure 0.00    
Perceived Need  1, 366 10.07 0.0017 
Yes 0.00    
No 0.03    
Prior Experience  1, 366 96.61 <0.0001 
Yes -0.38    
No 0.00    
Educated Patient About 
Pharmacogenomics 
 1, 366 0.02 0.9021 
Advocated   1, 366 0.37 0.5447 
Innovativeness  4, 363 0.32 0.8678 
Complexity  2, 365 2.35 0.0969 
Trialability  2, 365 5.12 0.0018 
Yes -1.09    
No 1.27    
      Unsure 0.00    
Relative Advantage  1, 366 41.45 <0.001 
Yes -1.45    
No 0.00    
Communication  2, 365 3.49 0.0319 
                        Less than 2 Forms 2.03    
                        3-4 Forms -0.12    
                        5-6 Forms 0.00    
*β0: 24.10 
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Table 16: ANOVA-General Attitude β df1, df2 F p 
Age  5, 362 0.79 0.5588 
Degree  8, 359 2.07 0.0383 
PhD -3.28    
DNP -5.46    
                                   CNS -7.29    
                                   NP -4.85    
 MSN -5.08    
      Diploma -4.14    
        Associate -4.18    
LPN -3.35    
BSN 0.00    
Certification  1, 366 2.48 0.1167 
Currently Working  1, 366 0.78 0.3790 
Ruralality  1, 366 1.21 0.2731 
Associated with Pharmacogenomic Research 
Site 
 1, 366 2.92 0.0883 
Work Setting  7, 360 1.2 0.3004 
Previous Genomic Education  1, 366 0.09 0.7674 
Perceived Genomic Knowledge  4, 363 0.38 0.8253 
Perceived Pharmacogenomic Knowledge  4, 363 0.71 0.5655 
Previous Pharmacogenomic Education  1, 366 0.29 0.5878 
Available Pharmacogenomic Tests  2, 365 3.16 0.0437 
Yes -1.05    
No -0.76    
      Unsure 0.00    
Perceived Need  1, 366 6.45 0.0116 
Yes 0.00    
No 0.72    
Prior Experience  1, 366 96.61 <0.0001 
Yes -0.01    
No 0.00    
Educated Patient About Pharmacogenomics  1, 366 0.26 0.6138 
Advocated   1, 366 0.03 0.8544 
Innovativeness  4, 363 0.91 0.4576 
Complexity  2, 365 1.55 0.2146 
Trialability  2, 365 4.84 0.0026 
Yes -0.10    
No -0.03    
      Unsure 0.00    
Relative Advantage  1, 366 26.21 <0.001 
Yes -1.23    
No 0.00    
Communication  2, 365 4.17 0.0163 
                                   Less than 2 Forms 0.69    
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                                 3-4 Forms -0.17    
                                 5-6 Forms 0.00    
*β0: 18.45 
 
[F(1, 366)=5.66, p=0.0179], prior experience [F(1, 366)=73.29, p<0.0001], 
communication behavior [F(2, 365)=6.23, p=0.0022], ruralality [F(1, 366)=4.65, 
p=0.0317], type of oncology setting [F(7, 360)=2.10, p=0.0356], observability of 
pharmacogenomic testing [F(2, 365)=4.28, p=0.0147], perceived need of 
pharmacogenomic testing [F(1, 366)=9.61, p=0.0021], relative advantage [F(1, 
366)=40.07, p<0.0001], and trialability [F(3, 364)=3.87, p=0.0097].  A Bonferroni post-
hoc test was completed and the categories within the communication behavior of greater 
than three modes of communication were combined due to their similarity.  In addition, 
similar attitudes towards pharmacogenomic testing specifically related to oncology were 
found between inpatient oncology units and university or college settings. 
Multicollinearity was not found among any of these variables. 
Finally, regression models were generated for each of the attitude scores, general 
attitude, attitude specifically related to pharmacogenomic testing in oncology, and the 
combination of both. The significant predictors that were found in the one-way ANOVA 
were utilized as indicator variables in the regression models.  A forward regression model 
was initially conducted.  Then a backward elimination was performed.  Finally, a 
stepwise regression model was conducted. 
The forward regression model for overall attitude towards pharmacogenomic 
testing revealed five indicator variables, communication behavior, observability, prior 
experience, perceived need, and relative advantage, created a significant model [F(5, 
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Table 17: ANOVA-Attitude Related to 
Oncology 
β df1, df2 F p 
Age  5, 362 1.13 0.3430 
Degree  8, 359 0.36 0.9394 
Certification  1, 366 0.12 0.7323 
Currently Working  1, 366 0.91 0.3417 
Ruralality  1, 366 4.65 0.0317 
                                 Rural -0.73    
                                 Urban 0.00    
Associated with Pharmacogenomic 
Research Site 
 1, 366 1.03 0.3098 
Work Setting  7, 360 2.10 0.0356 
 Inpatient Unit 1.86    
 Outpatient Unit 1.88    
 Hospice 1.13    
 Pain Management -1.95    
 Home Health -0.06    
 University 0.57    
 Physician‟s Office 2.18    
 Research  0.00    
Previous Genomic Education     
                                Yes 0.00 1, 366 5.66 0.0179 
No 0.59    
Perceived Genomic Knowledge     
Perceived Pharmacogenomic Knowledge  4, 363 1.86 0.1173 
Previous Pharmacogenomic Education  4, 363 1.76 0.1361 
Available Pharmacogenomic Tests  1, 366 1.8 0.1813 
Yes -0.90 2, 365 4.28 0.0147 
No -0.26    
      Unsure 0.00    
Perceived Need     
Yes -0.40 1, 366 9.61 0.0021 
No 0.00    
Prior Experience     
Yes -0.21 1, 366 73.29 <0.0001 
No 0.00    
Educated Patient About 
Pharmacogenomics 
    
Advocated   1, 366 0.92 0.3388 
Innovativeness  1, 366 2.31 0.1295 
Complexity  4, 363 0.91 0.4570 
Trialability  2, 365 2.37 0.0969 
Yes -0.05 2, 365 3.87 0.0097 
No 0.95    
      Unsure 0.00    
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Relative Advantage     
Yes -0.23 1, 366 40.07 <0.001 
No 0.00    
Communication     
                                Less than 2 Forms 0.69 2, 365 6.23 0.0022 
                                3-4 Forms -0.17    
                                5-6 Forms 0.00    
*β0: 7.93 
 
362)=20.74, p<0.0001] (Table 18).  Both the backwards and stepwise regression model 
revealed the same conclusion.  
Regression models were also conducted for general attitude towards 
pharmacogenomic testing (Table 18).  The forward regression model revealed four 
indicator variables: communication behavior, relative advantage, prior experience, and 
perceived need [F(4, 363)=17.69, p<0.0001].  Additionally a stepwise regression was 
conducted to reveal the same indicator variables. However, a backward elimination 
revealed six indicator variables: communication behavior, relative advantage, prior 
experience, trialability, highest degree obtained, and perceived need [F(6, 361)=11.11, 
p<0.0001].  Since two different models were found, AIC, BIC and PRESS criterion were 
utilized. The forward elimination model was found to be the best model because it had 
the lowest AIC, BIC, and PRESS. 
Finally, a forward regression model for attitude towards pharmacogenomic testing 
specifically related to oncology revealed six indicator variables: communication 
behavior, relative advantage, perceived need, setting, prior experience, and observability 
[F(6, 361)=17.22, p<0.0001] (Table 18).  A backward elimination revealed that seven 
indicator variables: communication behavior, oncology setting, prior experience, 
previous genomic education, observability, relative advantage, and perceived need,  
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Table 18: 
Regression 
for 
Attitude 
 F R
2
 β SE β 
Overall 
Attitude 
Relative 
Advantage 
20.74 0.22 4.14 0.71 
Perceived Need    -3.82 0.96 
Communication 
Behavior   
-1.44 0.48 
Observability   0.48 0.24 
Prior Experience   3.59 0.42 
General 
Attitude 
Relative 
Advantage 
17.69 0.14 2.02 0.47 
Perceived Need    -1.95 0.64 
Communication 
Behavior 
  -0.78 0.32 
Prior Experience   1.98 0.23 
Degree
1
   - - 
Trailability
1
   - - 
Attitude 
Related to 
Oncology 
Field 
Relative 
Advantage 
17.22 0.22 2.04 0.34 
Perceived Need    -1.76 0.46 
Communication 
Behavior   
-0.69 0.22 
Observability   0.35 0.16 
Prior Experience   1.1 0.21 
Setting   -0.08 0.03 
Previous Genomic 
Education
2
 
  - - 
1
: Included only in backward elimination; 
2
: Included only in backward elimination 
 
created a significant model [F(7, 360)=15.27, p<0.0001].  Additionally a stepwise 
regression revealed the same significant model as the forward regression model.  The 
forward elimination model was found to be the best model because it had the lowest AIC, 
BIC, and PRESS.   Residual analyses were completed for all significant models and no 
outliers were found. 
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Summary.  Attitude (persuasion) is influenced by several factors according to 
Rogers‟ (2003).  Variables that influence knowledge as well as perceived characteristics 
of the innovation influence one‟s attitude toward the innovation. Within this study, 
overall attitude score toward pharmacogenomic testing was influenced by communication 
behavior, prior experience with pharmacogenomic testing, perceived need of 
pharmacogenomic testing as well as characteristics of the innovation including 
observability, trialability, and relative advantage.   
Oncology nurses who utilized less information sources, had no prior experience 
with pharmacogenomic testing, lower observability, trialability, and relative advantage, 
and a lower perceived need for pharmacogenomic testing within the area of oncology had 
a significantly higher overall attitude score, in which a higher score indicated a more 
negative attitude towards pharmacogenomic testing.   
Regression models revealed that overall attitude towards pharmacogenomic 
testing was more accurately predicted by communication behavior, prior experience, 
perceived need and characteristics of the innovation including observability and relative 
advantage.   
General attitude toward pharmacogenomic testing was influenced by several 
variables including perceived need of pharmacogenomic testing, communication 
behavior, prior experience with pharmacogenomic testing, personality variable of 
educational degree, and characteristics of the innovation: trialability and relative 
advantage.  
Oncology nurses with a Bachelor‟s degree, lower perceived need of 
pharmacogenomic testing, no prior experience with pharmacogenomic testing, and less 
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information sources had a significantly higher general attitude score.  In addition, 
respondents who felt that pharmacogenomic testing were not modifiable and not 
promising within the field of oncology also had a significantly higher general attitude 
score.  Therefore, these respondents had a more negative opinion of pharmacogenomic 
testing. Regression models revealed that general attitude towards pharmacogenomic 
testing was more accurately predicted by communication behavior, perceived need of 
pharmacogenomic testing, prior experience with pharmacogenomic testing, and the 
characteristic of the innovation of relative advantage.   
Attitude toward pharmacogenomic testing specifically related to the field of 
oncology was influenced by several variables associated with the guiding theory 
including previous genomic education, prior experience, ruralality, communication 
behavior, type of oncology setting, perceived need, and characteristics of the innovation: 
observability, relative advantage and trialability of pharmacogenomic testing. 
Respondents with no previous genomic education, no prior experience with 
pharmacogenomic testing, utilized less informational sources, lower observability, 
trialability, and relative advantage, worked in an urban, worked in a physician‟s office, 
and a lower perceived need of pharmacogenomic testing had a negative attitude score 
towards pharmacogenomic testing specifically related to the field of oncology. 
Regression models revealed that attitude towards pharmacogenomic testing specifically 
related to the oncology field was more accurately predicted by communication behavior, 
perceived need of pharmacogenomic testing, prior experience with pharmacogenomic 
testing, and characteristics of the innovation: relative advantage and observability.  
 Aim # 3 was partially supported in addressing which relationships were 
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associated with attitudes of oncology nurses in the state of North Carolina and only a few 
of the variables successfully predicted the dependent variable of overall attitude, general 
attitude and attitude specifically related to oncology. 
Aim # 4 Analyses 
Aim # 4 analyses addressed the following research question, “what are the 
relationships between the support for use of pharmacogenomic testing in the oncology 
field and the following variables: actual genomic and pharmacogenomic testing 
knowledge, overall attitudes towards pharmacogenomic testing, attitudes specifically 
related to Tamoxifen, age, years of experience in the oncology setting, education level, 
certification in oncology, currently practicing in oncology field, time since last 
genomic and pharmacogenomic education, association with a pharmacogenomic 
testing research site and perceived genomic and pharmacogenomic testing knowledge? 
The same statistical analyses conducted in Aims # 2 and # 3 were also performed 
for this Aim.  A contingency table was calculated for each categorical variable with 
support for use of pharmacogenomic testing.  A Pearson‟s chi square test was calculated 
for each categorical variable to determine whether the distribution of each item differed 
over the levels of each categorical variable.  The contingency table revealed that work 
setting (19.57, p=0.012) was not associated with support for use.  
Furthermore, a one-way ANOVA was conducted to determine whether support 
for use differ significantly within each of the variables (Table 19).  There was a 
significant effect of perceived basic genomic knowledge on the support for use of 
pharmacogenomic testing [F(4, 363]=2.61, p =0.0357].  A Bonferroni post-hoc test was 
completed and the categories of poor and fair perceived genomic knowledge were 
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combined due to their similarity.  Multicollinearity was not found among any of these 
variables. 
Table 19: 
ANOVA-
Support of Use 
β df1, df2 F p 
Age  5, 362 0.91 0.4720 
Degree  8, 361 0.29 0.9681 
Certification  1, 366 0.09 0.7586 
Currently 
Working 
 1, 366 0.66 0.4189 
Ruralality  1, 366 0.39 0.5331 
Association with 
Pharmacogenomic 
Research Site 
 1, 366 1.58 0.2093 
Work Setting  7, 360 1.79 0.0786 
Perceived 
Genomic 
Knowledge 
 4, 363 2.61 0.0357 
Poor -0.364    
           Fair -0.361    
Good -0.365    
         Very Good -0.333    
       Excellent 0.00    
Perceived 
Pharmacogenomic 
Knowledge 
 4, 363 2.04 0.0889 
*β0: 2.0 
 
Finally, regression models were generated for support for use of 
pharmacogenomic testing (Table 20).  The forward regression model, backward 
elimination and stepwise regression model for support for use revealed that perceived 
basic genomic knowledge created a significant model [F(4, 363)=11.35, p=0.0008].  
Residual analyses were completed for all significant models and no outliers were found. 
Summary.  Support for use was only influenced by perceived basic genomic 
knowledge.  Respondents with higher perceived basic genomic knowledge had more 
support for use.  Regression models to support the finding that support for use was 
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accurately predicted by perceived genomic knowledge.  Aim # 4 was partially supported 
in addressing which relationships were associated with support for use of oncology 
nurses in the state of North Carolina and only a one variable successfully predicted the 
dependent variable of support for use. 
Table 20: 
Regression for 
Support for Use 
 F R
2
 β SE β0 
 Perceived Genomic 
Knowledge 
11.35 0.03 0.12 0.036 
 
Interest in Continuing Education 
An additional question assessed interest in continuing education regarding 
pharmacogenomic testing. Figure 6 indicates the interest in continuing education among 
oncology nurses in North Carolina, which revealed that they were more interesting in CE 
web-based or classroom courses. 
 
 
 
 
 
 
 
 
 
 
Figure 6: Continuing Education Interest
0
10
20
30
40
50
60
70
80
Grand Rounds  Seminar or
Lecture
 CE Course  AHEC Course  Web Based CE
Course
 Half Day
Conference
 All Day
Conference
 Interdisciplinary
Course
P
e
rc
e
n
t 
(%
)
 86 
 
Summary 
 Descriptive statistics were completed for Aim #1, which included univariate 
analysis as well as frequency and percentage analyses.  Additionally, contingency tables 
were created for each item on the knowledge and attitude scales as well as support for 
use.  An ANOVA was completed for each dependent variable to determine indicator 
variables appropriate for utilization in regression models.  Finally, variable selection 
methods were conducted to determine the best fitting model for each dependent variable 
within each aim. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
Chapter V 
Discussion 
Rogers‟ Diffusion of Innovation theory guided this study to assess the adoption of 
pharmacogenomic testing into the oncology practice by assessing oncology nurses‟ 
knowledge, attitudes, and support for use of pharmacogenomic testing.  Within this 
chapter, the key findings and conclusions are addressed. Discussion of limitations of the 
study, implications for education and practice, and recommendations for future research 
are also presented.  
Key Findings 
Perceived and actual knowledge (Awareness).  Findings from this study were 
consistent with Roederer et al.‟s (2012) study that assessed perceived and actual 
knowledge of pharmacogenomic testing among pharmacists.  Both studies revealed poor 
to fair perceived knowledge of genomic and pharmacogenomic testing, which 
corresponded with the assessment of their actual knowledge in which the respondents 
only answered about half of the questions correctly.  Van Riper et al. (2012) also found 
the same results within their study which included multiple disciplines.  No study has 
been conducted with solely nurses assessing their perceived and actual knowledge; 
however, the perceived knowledge findings did coincide with Dodson & Lewellan (2011) 
in which nursing students felt that they had a poor perceived knowledge of genomics. 
Attitude (Persuasion) toward pharmacogenomic testing.  The findings were 
similar to the other published literature.  Roederer et al. (2012) pharmacists had an 
 88 
 
overall positive attitude regarding pharmacogenomic testing.  Pharmacists had an overall 
mean score of 3.9 out of 5 for how comfortable they are with determining their initial 
dose of Warfarin; in which 5 was positive and 1 was a more negative attitude (Roederer 
et al., 2012).  Additionally, these pharmacists felt that pharmacogenomic testing would 
lead to decreased adverse drug reactions and better patient outcomes.  Similarly, El-Ibiary 
(2008) concluded that pharmacists had a positive attitude towards pharmacogenomic 
testing as well.  Several studies concluded mixed attitudes towards pharmacogenomic 
testing (Avard et al., 2009; Egalite et al., 2007; Fargher et al., 2007; Hoop et al., 2010; 
Rogausch et al., 2006).  However, Hedgecoe (2006), Kadafour et al. (2009), and Tamaoki 
et al. (2007) found a more negative attitude towards pharmacogenomic testing among 
clinicians.  These studies were conducted much earlier than the former studies, which 
may reveal that the findings from this study as well as the more recent studies suggest 
that attitudes concerning pharmacogenomic testing among clinicians are becoming more 
positive. 
Support for use (Decision).  No other study has been conducted with nurses on 
their utilization of pharmacogenomic testing. Therefore this study enhances the literature 
to provide an understanding of how nursing utilizes pharmacogenomic testing within 
their practice. 
Innovativeness.  According to Rogers (2003), the superlative rate of adoption 
follows an S curve when plotted over time as seen in Figure 3.  Based on normal 
populations, innovators consisted of 2.5% of the population, 13.5% were early adopters, 
34% were early majority, 34% were late majority, and 16% were traditionalists.  
According to the results, this study had far more innovators and early adopters.   
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Furthermore, the percentage of late majority and traditionalist were extremely 
low.  According to Rogers (2003), the adoption of the innovation quickly occurs once the 
early adopters adopt the new innovation.  Since this sample has more innovators and 
early adopters than the typical percentages, the rate of adoption may increase for this 
sample, which may lead to the early uptake of innovation by this sample.   However, 
oncology nurses who are laggards or are a part of the late majority may have not even 
completed the survey, which may have lead to a skewed distribution of the degree of 
innovativeness for oncology nurses.  Therefore, these results should be scrutinized before 
generalizing to the entire population of oncology nurses.  
Concepts Related to Theory 
Relationships Associated with Knowledge (Awareness)  
Knowledge is influenced by several factors according to Rogers (2003).  Prior 
conditions, including prior experience, innovativeness, perceived need, and work 
environment, as well as characteristics of the decision-making unit, which includes 
ruralality, communication behavior, and personality variables affect one‟s knowledge of 
the innovation.   
Total genomic knowledge.  Prior experience with the innovation was the only 
prior condition that was associated with total actual genomic knowledge.  Perceived need, 
work environment and innovativeness may have not been associated with this concept for 
a variety of factors.   Oncology nurses may have perceived a need for the innovation 
despite their knowledge of genomics.  They may believe that the innovation is better than 
the current treatment available for their patients, but not necessarily have had adequate 
education on the topic.  In addition, despite the fact that they may feel that this innovation 
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is needed in oncology, they may or may not be interested in learning more about 
genomics because they may feel that it does not directly relate to their scope of practice.  
Innovativeness may have not been associated with total genomic knowledge based on the 
fact that this sample had a different composition of categories as compared to Rogers‟ 
Diffusion of Innovation Theory (Rogers, 2003) as well as the conclusions given in the 
previous section on innovativeness.  Work environment may not have been associated 
with this variable due to lack of an accurate measure of this concept.  A different method 
of measurement for this concept needs to be addressed in order to determine whether 
these concepts are truly not associated with total genomic knowledge.  In future studies, 
work environment should be measured as the degree of flexibility and creativity one has 
in their place of work rather than the work setting due to the fact that Rogers (2003) 
stated that a flexible work environment increases the rate of adoption of an innovation.  
Ruralality and several personality variables such as perceived basic genomic 
knowledge, previous genomic education, and certification in oncology nursing was 
associated with this concept.  Working in an urban setting had a significantly higher 
mean total actual genomic knowledge score which could be due to more access and better 
resources for knowledge acquisition pertaining to genomics in general. Certification in 
oncology nursing may have been associated with increased knowledge due to the 
requirement for continual education in oncology in order to maintain the certification.  
Therefore, these nurses may have an enhanced knowledge of genomics based on more 
exposure to continuing education courses.  Also many of the continuing education 
courses include information on current drug therapy and tumor profiling which have a 
genomic component.  On the other hand, communication behavior was not associated 
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with this concept. Communication was measured by the types of media one utilized 
within the last week.  However, a more efficient measurement of this concept would be to 
assess what type of media does the respondent utilized to obtain information for different 
purposes.  No other studies have been published that assessed the association between 
these variables and total actual genomic knowledge.   
Basic genomic knowledge.  The same concepts that were associated with total 
genomic knowledge were the same concepts that were associated with basic genomic 
knowledge, with the addition of age and perceived need.  Age was the only additional 
personality variable that was associated with basic genomic knowledge and not 
associated with total genomic knowledge.  This may due to the fact that nursing programs 
are now mandated to include basic genomic competencies within their nursing programs.  
Therefore, integration of genomics in nursing programs may lead a significantly higher 
knowledge of basic genomics as compared to nurses who have not had this integration 
within their initial nursing studies.  In addition, perceived need may have been associated 
with basic genomic knowledge due to the fact that nurses who had a better understanding 
of basic genomics felt that this innovation is needed within the oncology field because 
they understand the usefulness of basic genomic testing which can be directly correlated 
with the usefulness of genomic testing for the guidance of drug therapy. 
Similarly, innovativeness, work environment, and communication behavior were 
not significantly associated with the total basic genomic knowledge score.  These 
relationships are most likely due to similar reasons given in the previous section. 
  Pharmacogenomic knowledge.  The concepts associated with 
pharmacogenomic knowledge were very similar to the concepts that were associated with 
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total genomic knowledge.  The concepts within the prior conditions were the same.  
However, the characteristics of the decision-making unit that were associated with total 
genomic knowledge were the same for pharmacogenomic knowledge except that 
ruralality had no relation.  In addition, the personality variable of previous 
pharmacogenomic education was related to an increase in pharmacogenomic knowledge, 
which would be expected.  However, ruralality may have not been associated with 
pharmacogenomic knowledge because of the encompassing lack of pharmacogenomic 
education and access within both rural and urban settings. 
Innovativeness, work environment, perceived need of pharmacogenomic testing, 
and communication behavior were not significantly associated with the total 
pharmacogenomic knowledge score. These four concepts may not be associated with 
total pharmacogenomic knowledge due to similar reasons given for the variable of total 
genomic knowledge. 
Relationships Associated with Attitude (Persuasion)  
Attitude (persuasion) is influenced by several factors according to Rogers‟ (2003).  
Variables that influence knowledge as well as perceived characteristics of the innovation 
which include relative advantage, compatibility, complexity, trialability, and 
observability, influence one‟s attitude toward the innovation. 
Overall attitude.  All of the perceived characteristics of the innovation were 
associated with overall attitude except complexity. Complexity of the innovation may not 
have been associated with this variable due to lack of an accurate measure of this 
concept.  Development of a different method of measurement for this concept needs to be 
addressed in order to determine whether this concept is actually not associated with 
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overall attitude.  Complexity should also measure whether the nurse doesn‟t know if the 
innovation is complex and therefore, the innovation could be deemed complex with either 
answer of the belief that this innovation is complex or the uncertainly whether it is 
complex.    
Communication behavior was associated with overall attitude.  Utilization of less 
media sources for information acquisition was associated with a more negative attitude, 
which could be reveal that the less  informed a person is, the more skeptical they are of 
new ideas. Additionally, a lower perceived need, less experience and knowledge of the 
innovation were all associated with a more negative overall attitude which could be due 
to the fact that knowledge acquisition must be obtained prior to persuasion that the 
innovation is positive.   
Innovativeness, work environment, ruralality, and some personality variables 
were not associated with overall attitude.  Work environment and innovativeness may not 
be associated with attitude due the reasons given for the knowledge variables.  Ruralality, 
age, educational degree, and certification in oncology were more closely associated with 
the variable of knowledge with Rogers‟ Diffusion of Innovation Theory.  Therefore, these 
concepts may not be good predictors of attitude. 
General attitude.  Many of the same concepts that were associated with overall 
attitude were also associated with general attitude.  However, one difference found was 
that within this sample, nurses with a Bachelor‟s degree had a more negative general 
attitude towards pharmacogenomic testing.  This finding may be due to the fact that the 
majority of the sample had a bachelor‟s degree and small differences could be detected 
within this group that could not be detected within the other groups.   
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Innovativeness, work environment, ruralality, some personality variables, and 
characteristics of the innovations including observability and complexity of the 
innovation were not associated with general attitude.  Observability of the innovation 
may not be associated with general attitude toward pharmacogenomic testing due to the 
nurses‟ preconceived notion of pharmacogenomic testing based on word of mouth rather 
than actually observing pharmacogenomic testing in practice.  The remaining concepts 
may not be associated with general attitude based on similar reasons given in the previous 
section. 
Attitude specifically related to the field of oncology.   Many of the same 
concepts that were associated with overall attitude were also associated with attitude 
specifically related to the field of oncology.  However, ruralality and work setting was 
associated with this concept.  Nurses within this sample who worked in an urban setting 
had a more negative attitude.  This result could be due to the excessive burden multiple 
tasks placed on these nurses and this innovation would add another new task to learn.  
Rural settings may have a more flexible and creative work environment due less stress 
that urban, academic medical centers often are consumed with.  However, a more 
negative attitude was found among nurses that work in physician‟s office, which may 
also be related to a less flexible work environment due to the time constraints with each 
patient.  This also may be the explanation behind why inpatient oncology units have a 
more negative attitude.   
Furthermore, innovativeness, some personality variables, and complexity of the 
innovation were not associated with attitude specifically related to the field of oncology.  
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These concepts may not be associated with attitude specifically related to the field of 
oncology due to similar reasons given in the previous section. 
Relationships Associated with Support for Use (Decision) 
Support for use is influenced by several factors according to Rogers‟ (2003).  
Variables that influence knowledge and attitude also influence support for use according 
to this theory, including prior conditions, characteristics of the decision-making unit and 
perceived characteristics of the innovation. 
Support for use.  Support for use was only associated with perceived basic 
genomic knowledge.  This may be due to the fact that the support for use was only 
measured by one question.  Future analysis should utilize ordinal regression since this 
concept is an ordinal variable.  This analysis may enhance the ability to determine 
accurate associations within the guiding framework. 
Discussion 
Several studies have been conducted on the variables that relate to adoption of an 
innovation by nursing (Bonner & Sando, 2008; Brown, Wickline, Ecoff, & Glaser, 2008; 
Chang & Lui, 2008; Jenkins, 1999; Jones, 1997; Kitson, 2009; van der Weide & Smits, 
2004; Weng, Huang, Huang, & Wang, 2012; Wilcox, 2009).  Jenkins (1999) and Weng et 
al. (2012) only addressed variables that may play a key role in the enhancement of 
knowledge based on the perceptions of nursing.  However Wilcox (2009) revealed that 
inadequate time, lack of perceived knowledge, and lack of prior experience with the 
innovation translated to poor knowledge acquisition.  These findings coincide with the 
findings from this study in that the mean knowledge scores for the total genomic, basic 
genomic and pharmacogenomic testing were predicted by perceived genomic knowledge 
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and prior experience with the innovation.  However Wilcox (2009) did not address 
certification in nursing, which reveals the reason a different variable was identified that 
influenced knowledge.  Furthermore, perceived need of the innovation was not addressed 
by Wilcox (2009).  However Kitson (2009) revealed that perceived need of the 
innovation significantly influences the rate of adoption of an innovation.  Therefore, this 
study reveals that perceived need of the innovation first influences knowledge 
acquisition.  In addition, no studies have been conducted that specifically assess variables 
that influence knowledge of pharmacogenomic testing in nursing; therefore this study 
adds information to the literature concerning what key factors play a role in the 
improvement of knowledge among nurses regarding pharmacogenomic testing. 
Brown et al. (2008) and Chang & Liu (2008) revealed that flexibility increases 
diffusion of an innovation.  This coincides with the finding that trialability is associated 
with attitude towards pharmacogenomic testing which leads to diffusion of the 
innovation.  Furthermore, Van der Weide and Smits (2004) concluded that nurses‟ belief 
that the innovation is useful for nursing improves innovation of diffusion.  This finding is 
similar to the outcome that an increased relative advantage is associated with a more 
positive attitude.  Based on these results, trialability and relative advantage of the 
innovation improves diffusion of innovation by enhancing a more positive attitude 
towards the innovation.   
Roederer et al. (2012) revealed that attitude was not significantly different among 
different educational degrees for pharmacists.  However, this dissertation revealed that 
nurses with a Bachelor‟s degree had a negative attitude towards pharmacogenomic 
testing.  This variation could be due to the fact that this sample was comprises mainly of 
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Bachelor-prepared nurses which could have provided significant results based on small 
differences that could be detected which are not clinically relevant because there was not 
an adequate distribution of nurses for each degree to determine a true difference in 
attitude.  Furthermore, decreased complexity of the innovation has been shown to 
improve attitude towards the innovation (Rogers, 2003; Wilcox, 2009).  However, this 
study did not reveal a significant difference between attitudes based on the perceived 
complexity of the innovation.  This finding could be related to the measurement of the 
variable in which asked whether the innovation was difficult to understand.  This measure 
may be ambiguous and need for revision in future studies.  A suggestion for a better 
measure was given in the previous section on attitude.  Moreover, no studies have been 
conducted that assess the association between attitude of the innovation and the following 
variables: prior experience with the innovation, communication behavior, ruralality, age, 
and type of work setting.  Therefore, this study enhances the literature in that prior 
experience, communication behavior, working in an urban area, younger age and type of 
work setting play a key role in the attitude towards the innovation.  These variables 
should be assessed more carefully in future research. 
Furthermore, Jones (2007) revealed that diffusion of innovation was not predicted 
by innovativeness.  This coincides with this study‟s outcomes that innovativeness did not 
predict knowledge, attitude, or support for use.  In addition, according to Rogers (2003), 
multiple variables affect the decision (support for use) component.  However, this study 
only indicated one variable as associated with support for use.  This finding could be due 
to the measurement of support for use.  Only one question assessed this component.  
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Therefore, a more accurate analysis of this component of the theory which was discussed 
should be conducted in future research. 
Strengths and Limitations 
 
Strengths.  The study sample consisted of 2705 oncology nurses from the state of 
North Carolina with a 14.3% total response rate.  Despite this rather low response rate, 
based on previously published studies utilizing similar tools to access clinicians‟ 
knowledge, attitude and use of pharmacogenomic testing, this study has a much higher 
response rate.  Roederer et al. (2012) and Stanek et al. (2012) only had a response rate of 
7.7% and 3%, respectively.  Therefore, based on the power analysis conducted prior to 
the study and this response rate, this study had a sufficient power to generate significant 
results. 
Limitations.  Several limitations were found throughout this study.  These 
limitations were divided into separate categories. 
Study tools. Respondents who did not receive the questionnaire via email may or 
may not have access to the Internet.  Due to the fact that this questionnaire was 
completed solely on-line, respondents without Internet access may not have had the 
opportunity to complete the survey.   
Additionally, the Nursing Practice Questionnaire had a low Cronbach‟s alpha of 
only 0.58.  Therefore, only the individual items were analyzed due to the low reliability 
of this instrument.  Originally, Brett (1987) published a Cronbach‟s alpha of 0.82 for this 
instrument.  However, this study had multiple innovations that were analyzed.  Therefore, 
this study had more items utilized within the Cronbach‟s alpha.  Ultimately, due to the 
low reliability, this instrument does not translate well to the application of 
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pharmacogenomic testing. 
              Study sample.  Only 1230 of the respondents were sent an invitation to take the 
on-line questionnaire via electronic mail due to the lack of information provided by the 
North Carolina Board of Nursing.  Therefore the remainder of the sample were sent an 
invitation postcard via mail.  There was a possibility that the inconvenience of filling out 
an on-line survey could have provided the poor response rate.   
In addition, several of the sample may have retired from oncology nurses and did 
not feel that they should participate in the study due to length of time out of the field.  
They may have felt that this may skew the results.   
Furthermore, the list obtained from the North Carolina Board of Nursing also 
contained nurses interested in the field of oncology rather than solely nurses who work in 
the oncology field.  Therefore, some the population may have self-selected themselves 
out of this study due to the title indicating the assessment of knowledge and attitudes of 
oncology nurses.  This may also be an explanation of the low response rate. 
Finally, this study was only conducted with oncology nurses from North Carolina.  
Therefore, this may not translate well nationally or internationally among oncology 
nursing. 
Study variables.  The study would have benefited from utilizing ordinal 
regression to evaluate the concept of support for use since this is an ordinal variable.  
Another method could be utilizing different measures to assess support for use.  Rather 
than asking whether the nurse has ever used pharmacogenomic information in the past, a 
more effective technique could be also asking to identify what type of pharmacogenomic 
information they utilize in practice. 
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Implications for Education 
This study revealed that previous basic genomic education lead to an improved 
perceived knowledge of genomic and pharmacogenomic testing as well an overall higher 
actual knowledge score on both items.  Therefore, genomic and pharmacogenomic 
education is the key to an improvement in pharmacogenomic knowledge.  Most of the 
respondents felt that they had a poor perceived genomic knowledge and would benefit 
from continuing education.  Therefore, an opportunity for genomic and 
pharmacogenomic continuing education should be provided for this population.  Based 
on the results, oncology nurses identified CE courses as the most appealing.   A formal 
course that includes basic genomic and pharmacogenomic information as well as 
pharmacogenomic information specifically related to the oncology field should be 
developed to help improve perceived knowledge. 
Furthermore, integration of genomic and pharmacogenomic information with 
nursing schools may also improve perceived knowledge of this innovation.  Therefore, 
nursing curriculum should include genomic information throughout each course.  In 
addition, pharmacogenomic testing should be introduced to nursing students before the 
begin practicing to help improve their understanding and attitude of this innovation. 
Finally, nurses with a certification in oncology had a significantly higher 
perceived and actual genomic and pharmacogenomic testing knowledge.  Therefore, 
future educational endeavors should include the obtainment of such certifications.  
Provision of incentives for nurses who obtain their nursing certification in oncology may 
improve the acquisition of these types of certifications. 
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Implications for Practice 
 Findings from this study may provide helpful insight for the diffusion of 
pharmacogenomic testing within the oncology nursing field. Several indicator variables 
improved knowledge, attitude and support for use of pharmacogenomic testing.  
Awareness of variables that successfully predict improved knowledge among clinician 
will help formulate interventional studies that focus on the modifiable variables 
associated with the improvement in knowledge.  Therefore, oncology nurses could 
potentially enhance their perceived knowledge by attending genomic courses, which is 
also associated with improved knowledge acquisition.  Furthermore, oncology nurse 
certification has been shown to predict knowledge of the innovation.  Therefore, 
incentives should be provided for oncology nurses to obtain this type of certification due 
to the improvement in knowledge.   
The main variables that significantly indicated a positive attitude towards 
pharmacogenomic testing were prior experience, relative advantage, trialability, and 
observability of pharmacogenomic testing.  Therefore, easy assessable pharmacogenomic 
testing information, provision of a list of pharmacogenomic tests available for oncology 
drugs, and knowledgeable clinicians with prescriptive privileges concerning 
pharmacogenomic testing should improve oncology nurses' attitudes towards 
pharmacogenomic testing.   Educational courses related to specific pharmacogenomic 
testing should be made available to oncology nurses to help enhance their overall attitude 
towards this innovation based on the increased perceived need, relative advantage, and 
observability of this innovation.  Additionally, a more flexible work environment, which 
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allows for creative workflow will also improve attitude towards innovation according to 
this study.   
 In addition, support for use of pharmacogenomic testing significantly improved 
with a higher perceived genomic knowledge.  Therefore, educational courses about 
pharmacogenomic testing should help improve the support of use of pharmacogenomic 
testing.    
Finally, Van Riper et al. (2012) revealed that practicing nurses had a significantly 
lower score on average than pharmacists; whereas students in the healthcare field scored 
significantly higher than all of the practicing disciplines (Van Riper et al., 2012).  A 
reasonable explanation for this outcome could be related to the promotion of widespread 
integration of genomic information, in which students may be exposed to more genomic 
education in today‟s educational settings.  Therefore, future studies may reveal an 
increase of genomic knowledge such as pharmacogenomic testing within the practicing 
disciplines. 
Implications for Future Research 
Future research would benefit from an intervention study that includes an 
educational CE course concerning pharmacogenomic testing related specifically to 
oncology.  The intervention study should include testing of pre- and post- actual 
knowledge scores and attitude scores.  Additionally, key variables associated with the 
guiding theory should be assessed as well to further enhance the development of the 
literature. 
Moreover, a different analysis for support for use should be conducted in future 
research utilizing this theory.  Development of a support for use scale may also help 
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improve assessment of multiple variables that are associated with one another according 
to Rogers‟ Diffusion of Innovation Theory.  Additionally, a different measure for 
complexity should also be developed to help improve predictiveness of this variable.  
Currently, this concept was measured as whether pharmacogenomic testing is difficult to 
understand.  This concept could be ambiguous, in which it would benefit from alteration. 
The variable of working in an urban setting revealed a higher knowledge score 
but a more negative attitude towards the innovation.  A research study assessing the 
variables between rural and urban work setting including variation in staff and 
accessibility of pharmacogenomic testing would be beneficial to identify key factors that 
may have lead to this outcome. 
In addition, other fields may also benefit from this research including cardiology, 
psychiatry, etc. in order to determine key components of improving the rate of adoption 
of pharmacogenomic testing within that field.  This questionnaire can be modified to fit 
each type of setting to help identify key variables to improve the diffusion of 
pharmacogenomic testing specifically related to each field. 
Summary 
 Overall this study indicated several variables that improve oncology nurses' 
knowledge, attitude and support of use concerning pharmacogenomic testing. Therefore, 
based on the improvement of knowledge, attitude, and support for use the variables 
improved perceived genomic education, obtainment of an oncology certification in 
nursing, and experience with pharmacogenomic testing should ultimately improve the 
rate of adoption of this innovation. 
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 Implications for education, practice and future research were provided to help 
enhance the adoption of pharmacogenomic testing among oncology nurses.  Limitations 
of this study were also indicated to help researchers improve the accuracy of future 
research. 
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Appendix A: 
Data Request Form 
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Appendix B: 
Knowledge, Attitude and Support for Use Questionnaire-Pharmacogenomic Testing 
(KAQ-PGx) (IS and NPQ-PGx Included) 
A. Informed Consent 
 
1.  I have read the above information and give my consent to participate in the 
research study, "Knowledge and attitudes about pharmacogenomic testing 
among clinicians".  
         
B. Background Information 
 
2.   What age best describes you? 
 
20-29    30-39    40-49   50-59   60-69   70 or greater 
 
3.  Which of the following best describes you? 
 
PhD    DNP   CNS    NP    Diploma RN   Associate Degree RN    BSN   LPN     
Other (please specify)  
 
4.   Do you have a certification in oncology nursing? 
 
      Yes              No      
 
If pick yes, go to 5; If pick no, go to 6:  
 
            5.  Which nursing certification do you have? (Choose all that apply) 
 
                 OCN   CPON   CPHON   AOCN   CBCN   AOCNP   AOCNS 
 
6.  Are you currently practicing as a nurse in the oncology field? 
 
     Yes              No 
 
 If pick yes, go to 7; If pick no, go to 8: 
 
7.   How many years have you been practicing in the oncology field? 
 
                  Over 30 Years   25-29   20-24   15-19   10-14   5-9   1-4   Under 1 year 
 
8.   How long has it been since you worked as an oncology nurse? (skip to           
      question 12) 
 
                  Less than 1 year   1-5 years   6-10 years   11-20 years   Greater than 20 years 
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9.    Which type of setting do you work in? 
 
                   Rural   Urban 
 
10.  Do you work at any of these places of employment?  
 
-Carolinas Medical Center 
-Cone Health 
-Duke Health 
-ECU or Pitt County Memorial Hospital 
-New Hanover Regional Medical Center  
-UNC Healthcare 
 
                    Yes              No 
 
11.   In what type of setting do you work? 
 
Inpatient Oncology Unit 
Ambulatory Care/Outpatient Center 
  Hospice/Palliative Care 
Pain Management Clinic 
Cancer Risk Assessment Center 
Home Health Care 
University/College Setting 
Physician‟s Office 
Research/Laboratory 
Other (please specify)   
 
12.   If you have a specialty in oncology, what is it? 
 
Pediatric Hematology/Oncology 
Breast Cancer 
Gynecologic Oncology 
Gastrointestinal Cancer 
  Head and Neck Cancer 
Lung Cancer 
Genetics 
Radiation Therapy 
  Interventional Oncology 
Other (please specify)   
 
C. Individual Responsiveness Scale 
 
People respond to their environment in different ways. The statements below refer to 
some of the ways people can respond. Please work quickly, there are no right or wrong 
answers, just record your first impression. 
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13.   My peers often ask me for advice or information. 
 
          1 Strongly Disagree   2       3       4      5 Strongly Agree 
 
14.   I enjoy trying new ideas. 
 
        1 Strongly Disagree   2       3       4      5 Strongly Agree 
 
   15.   I seek out new ways to do things. 
 
         1 Strongly Disagree   2       3       4      5 Strongly Agree 
 
16.   I am generally cautious about accepting new ideas. 
 
                    1 Strongly Disagree   2       3       4      5 Strongly Agree 
 
17.   I frequently improvise methods for solving a problem when an answer is not   
        apparent. 
 
       1 Strongly Disagree   2       3       4      5 Strongly Agree 
 
18.   I am suspicious of new inventions and new ways of thinking. 
 
        1 Strongly Disagree   2       3       4      5 Strongly Agree 
 
19.   I rarely trust new ideas until I can see whether the vast majority of people  
        around me accept them. 
 
       1 Strongly Disagree   2       3       4      5 Strongly Agree 
 
20.   I feel that I am an influential member of my peer group. 
 
        1 Strongly Disagree   2       3       4      5 Strongly Agree 
 
21.   I consider myself to be creative and original in my thinking and behavior.  
 
        1 Strongly Disagree   2       3       4      5 Strongly Agree 
 
22.   I am aware that I am usually one of the last people in my group to accept  
        something new. 
        1 Strongly Disagree   2       3       4      5 Strongly Agree 
             23.   I am an inventive kind of person.  
                    1 Strongly Disagree   2       3       4      5 Strongly Agree 
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24.   I enjoy taking part in the leadership responsibilities of the group I belong to.  
        1 Strongly Disagree   2       3       4      5 Strongly Agree 
25.   I am reluctant about adopting new ways of doing things until I see them      
        working for people around me.   
 
        1 Strongly Disagree   2       3       4      5 Strongly Agree 
26.   I find it stimulating to be original in my thinking and behavior.  
        1 Strongly Disagree   2       3       4      5 Strongly Agree 
27.   I tend to feel that the old way of living and doing things is the best way.  
        1 Strongly Disagree   2       3       4      5 Strongly Agree 
28.   I am challenged by ambiguities and unsolved problems.  
                    1 Strongly Disagree   2       3       4      5 Strongly Agree 
29.   I must see other people using new innovations before I will consider them.  
                    1 Strongly Disagree   2       3       4      5 Strongly Agree 
30.   I am receptive to new ideas.  
                    1 Strongly Disagree   2       3       4      5 Strongly Agree 
 31.  I am challenged by unanswered questions.  
                    1 Strongly Disagree   2       3       4      5 Strongly Agree 
   32.  I often find myself skeptical of new ideas.  
        1 Strongly Disagree   2       3       4      5 Strongly Agree 
D. Background in Genetics/Pharmacogenomics 
 
33.   Have you had any of the following types of genetics education? (Select all  
        that apply) 
     No, I have had no education in genetics 
Grand Rounds 
Seminar or Workshop 
    CE Course 
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    Genetics Course in Graduate School 
    Undergraduate Genetics Course 
Other (please specify)  
 
When was your last genetics course? (If choose any answer other than „no‟ on question 
33) 
 
34.   Have you ever attended educational activities related to pharmacogenomic  
        testing? 
 
                    Yes      No 
 
35.   How would you rate your current understanding of genetics? 
 
     Excellent 
    Very Good 
    Good 
    Fair 
    Poor 
 
36.   How would you rate your current understanding of pharmacogenomic   
        testing? 
   Excellent 
Very Good 
    Good 
    Fair 
Poor 
 
37.   Are pharmacogenomic tests available at your place of employment, such as     
        HerceptestTM or AmpliChipTM CYP450 Test? 
 
        Yes        No         Do Not Know 
 
38.   Have you ever cared for a patient who has had a pharmacogenomic test? 
 
        Yes        No         Do Not Know 
 
39.   Have you ever educated a patient about pharmacogenomic testing? 
 
        Yes        No          
 
40.   Have you ever advocated for your patient to obtain pharmacogenomic 
        testing? 
 
        Yes        No          
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E. Basic Genomics Questions 
 
41.   Humans are over 99% identical at the DNA level. 
 
                    True       False       Do Not Know 
 
42.   Most cells in the human body contain 47 chromosomes. 
 
        True       False       Do Not Know 
 
43.  Every time the human body produces a sperm or an egg, approximately 3   
       billion nucleotides (bases) must be copied and packaged so they can be    
       passed along to future offspring.  
 
                   True       False       Do Not Know 
 
44.  The nucleotides (bases) in DNA, always match up the same way - Adenine  
       (A) always pairs with the Cytosine (C) and Guanine (G) always pairs with the    
       Thymine (T). 
 
       True       False       Do Not Know  
 
45.   A number of genetic conditions, such as Huntington‟s Disease, are caused by  
        a mutation in a single gene.  
 
       True       False       Do Not Know 
 
F. Questions About Pharmacogenomic Testing  
 
46.  Genetic variations can account for as much as 95% of the variability in drug  
       disposition and effects.  
 
       True       False       Do Not Know 
 
47.  Genetic determinants of drug response change over a person's lifetime.  
 
       True       False       Do Not Know 
 
48.  Subtle differences in a person's genome can have a major impact on how the   
       person responds to medications. 
 
       True       False       Do Not Know 
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49.  A pharmacogenomic test is available for postmenopausal women who are  
       taking or considering taking Tamoxifen to prevent the recurrence of breast  
       cancer. 
 
       True       False       Do Not Know 
 
50.  Pharmacogenomic testing is currently available for most medications. 
 
       True       False       Do Not Know 
 
 
The following text is about pharmacogenomic testing. Please read text carefully in order 
to answer the questions that follow.   
 
The effect of medication varies from person to person, which can be due to the 
fact that human genetic profiles are not identical.  Pharmacogenomic testing is defined as 
a genetic test that is used to guide a patient's drug therapy based on the individual‟s 
genetic make-up. Genetic variations mean that people break down drugs differently. This 
is the reason that one drug works on some patients, but has no effect on others or is not as 
effective, and that some patients experience an adverse drug reaction from one drug, 
while others can tolerate it. Pharmacogenomic testing will enable patients to be treated 
with medication adapted to their individual genetic profile and thus their own body.  This 
is called personalized medicine because it provides tailor-made treatment adapted to the 
individual. Pharmacogenomic testing is done through a blood test or cheek swab, which 
the healthcare provider must carry out before treating the patient. Healthcare providers 
can see what types of drugs the patient will benefit from before medication is prescribed, 
and thus the patient will get personalized medicine that is more effective and has fewer 
adverse drug reactions than the treatment offered today.  The test also means that patients 
with the same disease can be differentiated, so only those who will benefit from the 
medication should take it.  Patients with a different genetic profile can avoid taking 
medication that won‟t work for them. 
 
Based on this definition, please answer the remaining questions. 
 
G. Nursing Practice Questionnaire- NPQ-PGx 
 
51.   Have you heard of the term pharmacogenomic testing before this  
        questionnaire? 
 
                    Yes      No 
 If pick yes, go to 52; If pick no, go to 56: 
52.  Have you read about pharmacogenomic testing in journal articles, medication  
       labels, etc.? 
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       Yes      No 
 
53.  Have you observed pharmacogenomic testing in practice? 
 
        Yes      No 
 
54.   Have you acquired information about pharmacogenomic testing from any  
        other source? 
 
        Yes      No 
 
55.   How often do you use pharmacogenomic testing information in your nursing  
        care? 
 
                    Never     Sometimes     Always 
 
H. Position About Pharmacogenomic Testing 
 
56.  Do you believe that a nurse should use pharmacogenomic testing information  
       in their nursing care? 
                   Yes     No     Unsure  
57.  Do you believe that a nurse should educate their patients about the purpose,  
       benefits, limitations and risks of pharmacogenomic testing? 
 
       Yes     No     Unsure 
 
58.  Do you believe that pharmacogenomic testing will decrease the cost of  
       developing drugs? 
 
       Yes     No     Unsure 
 
59.  Do you believe that pharmacogenomic testing will help to decrease the  
       number of adverse drug reactions?  
 
       Yes     No     Unsure 
 
60.  Do you believe that pharmacogenomic testing is difficult to understand? 
 
       Yes     No     Unsure 
 
61.  Do you believe that the incorporation of pharmacogenomic testing can be  
       modified for specific settings? 
 
       Yes     No     Unsure 
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62.  How concerned are you that unauthorized persons may gain access to the  
       results of a patient‟s pharmacogenomic testing?  
 
                   1 Not Likely    2 Somewhat Likely   3 Likely        4 Very Likely 
63.  How concerned are you that your family‟s healthcare will be affected by your    
       pharmacogenomic testing results?  
 
       1 Not Likely    2 Somewhat Likely   3 Likely        4 Very Likely 
 
   64.  How concerned are you that pharmacogenomic testing may result in  
                   discrimination by employers and /or insurance companies? 
 
                   1 Not  Concerned  2 Somewhat Concerned    3 Concerned  4 Very Concerned 
 
65.  If you have other thoughts or concerns about pharmacogenomic testing,  
       please share them in the box below. 
 
I. Position About Pharmacogenomic Testing to Guide Tamoxifen Therapy 
 
  66.  Do you believe that oncology represents a particularly promising area for the  
                   use of pharmacogenomic approaches. 
 
                   Yes     No     Unsure 
 
   67.  Do you believe that Tamoxifen efficacy and side effects are in part  
                   genetically determined. 
 
                   Yes     No     Unsure 
 
68.  Do you believe tumor profiling is useful?  
 
       Yes     No     Unsure 
 
69.  How comfortable would you be having genetic information incorporated into  
       the determination of whether your patient should receive Tamoxifen? 
 
                   1 Not Comfortable       2       3      4 Very Comfortable 
 
70.  If you were the patient for whom hormonal therapy was being considered,  
       how comfortable would you be having genetic information used to determine  
       whether you should receive Tamoxifen or an alternative agent such as an  
       aromatase inhibitor? 
 
       1 Not Comfortable       2       3      4 Very Comfortable 
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71.  How much do you trust pharmacogenomic tests for determining your  
       patient‟s treatment? 
 
       1 Not Likely    2 Somewhat Likely   3 Likely        4 Very Likely 
 
72.  Do you have prescriptive privileges?  
 
                  Yes       No 
 
J. Questions for Clinicians with Prescriptive Privileges 
 
73.  How likely is it that you would look for pharmacogenomic information about  
       a drug prior to ordering the drug for your patient?  
 
       1 Not Likely    2 Somewhat Likely   3 Likely        4 Very Likely 
 
74.  If you were given the results of your patient‟s pharmacogenomic testing to  
       help guide your prescribing of a particular agent, how comfortable would you 
       be interpreting and using that information on your own? 
 
       1 Not Comfortable       2       3      4 Very Comfortable 
 
75.  Have you ordered a pharmacogenomic test before prescribing Tamoxifen? 
 
                   Yes    No 
 
76.  If you have not ordered pharmacogenomic testing before prescribing  
       Tamoxifen, what were your reasons for not ordering it? (Check all that apply) 
 
   I was not aware that this type of testing was available. 
   I do not know of or have access to a lab that performs this type of testing. 
   I have not seen convincing evidence of the clinical utility of this type of  
            testing. 
Clinical guidelines on how to use the results of this type of testing are 
                        lacking. 
Ordering the testing and waiting for results would delay patient treatment. 
    This type of testing is not covered by my patient‟s health insurance plans. 
    I do not feel confident about how to interpret and apply the results. 
    I am concerned about patient confidentiality and the privacy of genetic  
                        data. 
There are too many false positives, false negatives, and/or ambiguous  
                        results. 
This type of testing is too expensive. 
    Patients are not interested in having this type of testing 
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K. Future Educational Offerings 
 
77. Which of the following sources have you used at least once within the last 
      week in order to gain information such as current events, educational  
      opportunities, etc.? (Select all that apply). 
 
   TV 
    Radio 
    Newspaper 
    Weekly Magazine 
    Internet 
Other Sources (please specify)  
 
78.  Would you be interested in learning more about pharmacogenomic testing? 
 
        Yes    No 
 
79.  Which of the following educational offerings about pharmacogenomic testing  
        would you attend? (Select all that apply) 
 
    Grand Rounds 
    Seminar or Lecture 
    CE Course 
    AHEC Course 
    Web-based CE Course 
    Half-day Conference 
    All-day Conference 
    Interdisciplinary    
        Conference 
 
L.  Thank You 
 
 Thank you for participating in this study.  
If you would like to receive a copy of the correct answers for the True and False 
questions, email Crissy Dodson at chdodson@email.unc.edu 
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Appendix C: 
 
Individual Innovativeness Scale (IS) 
 
Directions: People respond to their environment in different ways. The statements below refer to some of 
the ways people can respond. Please indicate the degree to which each statement applies to you by marking 
whether you: Strongly Disagree = 1; Disagree = 2; are Neutral = 3; Agree = 4; Strongly Agree = 5 
Please work quickly, there are no right or wrong answers, just record your first impression. 
 
_______ 1. My peers often ask me for advice or information. 
_______ 2. I enjoy trying new ideas. 
_______ 3. I seek out new ways to do things. 
_______ 4. I am generally cautious about accepting new ideas. 
_______ 5. I frequently improvise methods for solving a problem when an answer is not apparent. 
_______ 6. I am suspicious of new inventions and new ways of thinking. 
_______ 7. I rarely trust new ideas until I can see whether the vast majority of people around me accept 
                   them. 
_______ 8. I feel that I am an influential member of my peer group. 
_______ 9. I consider myself to be creative and original in my thinking and behavior. 
_______10. I am aware that I am usually one of the last people in my group to accept something new. 
_______11. I am an inventive kind of person. 
_______12. I enjoy taking part in the leadership responsibilities of the group I belong to. 
_______13. I am reluctant about adopting new ways of doing things until I see them working for people 
                    around me. 
_______14. I find it stimulating to be original in my thinking and behavior. 
_______15. I tend to feel that the old way of living and doing things is the best way. 
_______16. I am challenged by ambiguities and unsolved problems. 
_______17. I must see other people using new innovations before I will consider them. 
_______18. I am receptive to new ideas. 
_______19. I am challenged by unanswered questions. 
_______20. I often find myself skeptical of new ideas. 
 
Scoring: 
 
Step 1: Add the scores for items 4, 6, 7, 10, 13, 15, 17, and 20. 
Step 2: Add the scores for items 1, 2, 3, 5, 8, 9, 11, 12, 14, 16, 18, and 19. 
Step 3: Complete the following formula: II = 42 + total score for Step 2 - total score for Step 1. 
Scores above 80 are classified as Innovators. 
Scores between 69 and 80 are classified as Early Adopters. 
Scores between 57 and 68 are classified as Early Majority. 
Scores between 46 and 56 are classified as Late Majority. 
Scores below 46 are classified as Traditionalists. 
In general people who score above 68 and considered highly innovative, and people who score below 64 
are considered low in innovativeness. 
 
Sources: 
 
Hurt, H. T., Joseph, K., & Cook, C. D. (1977). Scales for the measurement of innovativeness. Human 
Communication Research, 4, 58-65. 
 
McCroskey, J. C. (2006). Communication research measures: Individual innovativeness. Retrieved 
December 31, 2004, from http://www.jamescmccroskey.com/measures/innovation.htm 
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Appendix D: 
 
Informed Consent 
 
Thank you for your time and attention regarding this research study. The overall purpose 
of this study is to examine knowledge and attitudes about pharmacogenomic testing (the 
use of genetic testing to guide a patient's drug therapy) among oncology nurses. I am 
collecting data from oncology nurses in the state of North Carolina.  
 
Before agreeing to participate in this study, it is pertinent that you are aware of the items 
that apply to everyone that participates in this research study: (a) involvement in this 
study is entirely voluntary; (b) there are no risks expected for those who take part in this 
study and there is no cost to study participants; c) you will not benefit directly from 
taking part in this study, but knowledge may be gained that might profit others; (d) your 
involvement is anonymous - so you will not be asked to provide any identifying 
information; e) all data acquired from this study will be reported as group data in order 
that no individual can or will be recognized; f) I plan on utilizing the results for my 
dissertation; g) I plan on presenting the results of this study at local and national 
conferences; and h) I plan on publishing the results of this study. 
 
Participation in this study involves completing a survey. This survey starts out with some 
questions about you. Then there are basic genetics questions as well as questions 
designed to assess what you know and think about pharmacogenomic testing. Finally, 
there are some questions about future educational opportunities. Completion of the 
survey should take about 10-20 minutes. Please note that I am interested in your answers 
even if you have little or no background in genetics or pharmacogenomic testing.  
 
If you have questions or concerns about the study, please contact Crissy Dodson, RN, 
MSN, Doctoral Candidate, University of North Carolina-Chapel Hill School of Nursing 
by email (chdodson@email.unc.edu). 
 
All research on human volunteers is reviewed by a committee that works to protect your 
rights and welfare. If you have questions or concerns about your rights as a research 
subject you may contact, anonymously if you wish, the Institutional Review Board at 
919-966-3113 or by email to IRB_subjects@unc.edu. 
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